Upload
richard-gabriel
View
73
Download
1
Embed Size (px)
DESCRIPTION
Pharmaceutical medicines in development for Cancer. A report listing the 900 products in development with company names and disease area
Citation preview
Few things cause more fear and apprehension than a cancer diagnosis. But today—because of early detection and a steady stream of new and improved treatments—cancer increasingly can be managed and even beaten. But patients and their families are looking for more and bet-ter treatments, and America’s biopharmaceuti-cal research companies are responding.
Biopharmaceutical researchers are now work-ing on 981 medicines for cancer. Many are
some involve innovative research into using existing medicines in new ways.
Researchers’ deep commitment to patients and advancing science is at the core of the remark-
-
cancer deaths. The number of cancer survivors living in the United States has increased from 3 million in 1971 to nearly 12 million in 2008. The increase in survivors is attributed in large measure to earlier diagnosis and detection and better treatments and follow-up care.
America’s biopharmaceutical research com-panies are working on many new cutting-edge
-tabolism of cancer cells by depriving them of the energy provided by glucose.
(AML) that inhibits cancer cells with a mutation found in about a third of AML sufferers.
target the delivery of medicines to cancer cells, potentially overcoming some limita-tions of existing treatments.
Despite recent progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart
people a day. The hundreds of new medicines to treat cancer now being developed are our best hope for lessening the burden of cancer to patients, their families and society.
More Than 900 Medicines and Vaccines in
Clinical Testing Offer New Hope in the Fight
Against Cancer
Medicines in Development
CANCER
PRESENTED BY AMERICA’S BIOPHARMACEUTICAL
RESEARCH COMPANIES
2012 RE
PO
RT
111
66
121117
94
Lym
phom
a
Col
orec
tal C
ance
rLu
ng C
ance
r
Pro
stat
e C
ance
r
Bre
ast C
ance
r
67
Ski
n C
ance
r
Medicines in Development
for Selected Cancer Types
More Than
1.6 million New Cases of Cancer Are Expected This Year
Medicines in Development Cancer 20122
Lung Cancer
Liver Cancer
Leukemia
Kidney Cancer
Head/Neck Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Brain Cancer
Bladder Cancer 9
62
66
111
8
25
35
120
36
121
Multiple Myeloma
Lymphoma 117
57
Ovarian Cancer 63
Cancer-Related Conditions
Stomach Cancer
Solid Tumors
Skin Cancer
Sarcoma
Prostate Cancer
Pancreatic Cancer
94
58
21
67
280
23
38
Unspecified Cancer
Other Cancers 102
72
* Some medicines are listed in more than one category.
Medicines in Development for Cancer*
Medicines in Development for Cancer
BLADDER CANCER
Product Name Sponsor Indication Development Status*
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
second-line bladder cancer (see also breast, lung, ovarian, pancreatic, skin)
(908) 673-9000
AEZS-108 AEterna ZentarisBasking Ridge, NJ
(see also ovarian, prostate, other)
BC-819 (gene therapy)
BioCancell TherapeuticsJerusalem, Israel
(see also ovarian, pancreatic)www.biocancell.com
(mycobacterium cell wall-DNA complex)
Endo PharmaceuticalsChadds Ford, PA
non-muscle invasive bladder cancer(Fast Track)
Medicines in Development Cancer 2012 3
BLADDER CANCE
Product Name Sponsor Indication Development Status
EOquin®
apaziquoneAllerganIrvine, CA
Spectrum PharmaceuticalsIrvine, CA
non-invasive bladder cancer(Fast Track)
Folotyn®
pralatrexate(Orphan Drug)
Allos TherapeuticsWestminster, CO
(see also breast, lung, lymphoma)
icrucumab Eli LillyIndianapolis, IN
Bridgewater, NJ
(see also breast, colorectal)
tesetaxel GentaBerkeley Heights, NJ
second-line bladder cancer (see also breast, prostate, skin, stomach)
(908) 286-9800
Viventia BiotechnologiesMississauga, Canada
(see also head/neck)
BRAIN CANCER
Product Name Sponsor Indication Development Status
United TherapeuticsSilver Spring, MD
(see also sarcoma, other)(301) 608-9292
ABT-888(veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also breast, colorectal, lung, lymphoma, ovarian, prostate, skin, other)
(pan-HER inhibitor)Ambit BiosciencesSan Diego, CA
glioma(see also breast, lung)
AEE788 Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma (888) 669-6682
afatinibPharmaceuticals
glioblastoma(see also breast, head/neck, lung)
APN301
fusion protein)
Apeiron BiologicsVienna, Austria
neuroblastoma in children(see also skin) www.apeiron-biologics.com
Medicines in Development for Cancer
Medicines in Development Cancer 20124
BRAIN CANCER
Product Name Sponsor Indication Development Status
AR-67 Arno TherapeuticsFlemington, NJ
glioblastoma(see also leukemia, solid tumors) (862) 703-7170
ARC-100 Archer BiosciencesNew York, NY
glioblastoma (recurrent)(see also breast, prostate, skin)--------------------------------------------------neuroblastoma (combination therapy)--------------------------------------------------medulloblastoma (combination therapy)
-------------------------------------------
-------------------------------------------
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
glioblastoma(see also leukemia, lung, lymphoma, prostate, stomach)
Avastin®
bevacizumabGenentechSouth San Francisco, CA (see also breast, colorectal, lung,
ovarian, other)
Azedra™
(Orphan Drug)Cambridge, MA
neuroblastoma (pediatric) (Fast Track), paraganglioma, pheochromocytoma (Fast Track)
bafetinib CytRx Los Angeles, CA
second-line brain cancer (see also leukemia, prostate)
BKM120 Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma(see also breast, lung, other) (888) 669-6682
(Orphan Drug)
United TherapeuticsSilver Spring, MD
neuroblastoma (children)(301) 608-9292
cilengitide(Orphan Drug)
EMD SeronoRockland, MA
newly-diagnosed glioblastoma(combination therapy)(see also prostate)
(800) 283-8088
cintredekin besudotox(Orphan Drug) Phoenix, AZ
glioma (adolescents and children)(Fast Track) (602) 910-2617
Cotara®
monoclonal antibody TNT-1 (Orphan Drug)
Peregrine Pharmaceuticals recurrent glioblastoma(Fast Track)
CPP-1X Cancer Prevention Pharmaceuticals neuroblastoma
Medicines in Development for Cancer
Medicines in Development Cancer 2012 5
BRAIN CANCER
Product Name Sponsor Indication Development Status
crenolanib AROG Pharmaceuticals glioma (adults)(see also stomach)--------------------------------------------------glioma (pediatric)
-------------------------------------------
DCVax®-Brain
brain cancer vaccine(Orphan Drug)
Northwest BiotherapeuticsBethesda, MD
glioblastoma
EisaiWoodcliff Lake, NJ
second-line glioblastoma (see also head/neck, liver, skin, solid tumors, stomach)
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
glioma(see also skin, other)
EPO-806(patupilone)
Novartis PharmaceuticalsEast Hanover, NJ
brain metastases from lung cancer(see also prostate) (888) 669-6682
G-100 prophage cancer vaccine(vitespen)(Orphan Drug)
AgenusLexington, MA
newly-diagnosed glioma
G-200 prophage cancer vaccine(vitespen)(Orphan Drug)
AgenusLexington, MA
recurrent glioma
GliAtak™gene therapy(Orphan Drug)
AdvantageneAuburndale, MA
glioma
--------------------------------------------------brain cancer (children)
-------------------------------------------
GMB-Vax
dendritic cell cancer vaccineActivartis BiotechVienna, Austria www.activartis.com
(LRP directed peptide-drugconjugate)
GeronMenlo Park, CA
brain metastases
--------------------------------------------------glioma
-------------------------------------------
(BRaf protein kinase inhibitor)GlaxoSmithKline brain metastases from melanoma
(see also lung, skin)
Hycamtin®
topotecanGlaxoSmithKline metastatic brain cancer
Medicines in Development for Cancer
Medicines in Development Cancer 20126
Medicines in Development for Cancer
BRAIN CANCER
Product Name Sponsor Indication Development Status
(dendritic cell vaccine)(Orphan Drug)
Woodland Hills, CA
glioblastoma(818) 992-2907
Levulan® PDT
aminolevulinic acidDUSA PharmaceuticalsWilmington, MA
lonafarnib MerckWhitehouse Station, NJ
glioblastoma(800) 672-6372
Lucanix®
belagenpumatucel-LNovaRxSan Diego, CA
glioma(see also lung)
macitentan Actelion Pharmaceuticals USSouth San Francisco, CA
glioblastoma (combination therapy)
(anti-PDGFR-alpha mAb)AstraZenecaWilmington, DE
Gaithersburg, MD
glioblastoma(see also lung) (800) 236-9933
(301) 398-0000
mibefradil(T-type calcium channel inhibitor)(Orphan Drug)
Tau TherapeuticsCharlottesville, VA
glioblastoma
PharmacyclicsSunnyvale, CA
glioblastoma (combination therapy)
nimotuzumab(Orphan Drug)
YM Biosciences USALehigh Valley, PA
metastatic brain cancer, recurrent glioma (pediatric)(see also breast, prostate)
olaratumab(LY3012207)
Eli LillyIndianapolis, IN
Bridgewater, NJ
glioblastoma(see also ovarian)
Opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
glioma, glioblastoma(see also lung, ovarian, stomach, other)
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic glioma(see also colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Medicines in Development Cancer 2012 7
Medicines in Development for Cancer
BRAIN CANCER
Product Name Sponsor Indication Development Status
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent glioblastoma(see also leukemia, lymphoma, solid tumors)
(Orphan Drug)
OncovirWashington, DC
anaplastic astrocytoma (adolescents and children), glioblastoma (adolescents and children)
www.oncovir.com
PX-866 OncothyreonSeattle, WA
second-line glioblastoma (see also head/neck, lung, prostate) (206) 801-2100
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
glioma(see also colorectal, head/neck, lung, ovarian, pancreatic, sarcoma,skin, solid tumors)
rindopepimut(Orphan Drug)
Celldex TherapeuticsNeedham, MA (Fast Track)
--------------------------------------------------second-line glioblastoma (Fast Track)
-------------------------------------------
SB-313-xTZ Sangamo BiosciencesRichmond, CA
glioblastoma
SBG Biotec Pharmacon neuroblastoma (pediatric)www.biotec.no
SL-701(brain cancer vaccine)
Stemline TherapeuticsNew York, NY
glioma (adults)
--------------------------------------------------glioma (children)
(212) 831-1111-------------------------------------------
(212) 831-1111
SPRYCEL®
dasatinibBristol-Myers SquibbPrinceton, NJ
glioblastoma(see also breast, pancreatic, prostate, other)
in clinical trials
Tarceva®
erlotinib(Orphan Drug)
GenentechSouth San Francisco, CA
Farmingdale, NY
late-stage brain metastases, recurrent ependymoma (children), glioblastoma(see also breast, head/neck, leukemia, liver, lung, other)
(631) 962-0600
terameprocol Erimos Pharmaceuticals glioma (intravenous)(see also cervical, head/neck, solid tumors, other)
TGF-ß R1 inhibitor Eli LillyIndianapolis, IN
(see also liver)
Medicines in Development Cancer 20128
BRAIN CANCER
Product Name Sponsor Indication Development Status
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
astrocytoma(see also leukemia, multiple myeloma, pancreatic, sarcoma)
(cytosine deaminase gene therapy)
TocagenSan Diego, CA
glioblastoma
trans-sodium crocetinate (TSC)(Orphan Drug)
Diffusion PharmaceuticalsCharlottesville, VA
gliobastoma
(cellular immunotherapyvaccine)
TVAX BiomedicalLenexa, KS
glioma
VAL-083 Del Mar PharmaceuticalsVancouver, Canada
VB-111 VBL TherapeuticsOr Yehuda, Israel
glioblastoma(see also other) www.vblrx.com
Xeloda®
capecitabineGenentechSouth San Francisco, CA
newly-diagnosed glioma (adolescents and children)(see also colorectal, liver, stomach)
Zelboraf®
vemurafenibGenentechSouth San Francisco, CA
PlexxikonBerkeley, CA
brain metastases(see also colorectal, other)
BREAST CANCER
Product Name Sponsor Indication Development Status
MerckWhitehouse Station, NJ
breast cancer (diagnosis)(800) 672-6372
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ (see also bladder, lung, ovarian,
pancreatic, skin)(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, colorectal, lung, lymphoma, ovarian, prostate, skin, other)
(pan-HER inhibitor)Ambit BiosciencesSan Diego, CA
(see also brain, lung)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 9
BREAST CANCER
Product Name Sponsor Indication Development Status
acolbifene EndoCeuticsQuebec, Canada
AE37 peptide vaccine Antigen ExpressWorcester, MA
(see also ovarian)
afatinibPharmaceuticals
second-line metastatic breast cancer(see also brain, head/neck, lung)-------------------------------------------------- -------------------------------------------
ASCEND TherapeuticsHerndon, VA
breast cancer (prevention)
®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
HER2-positive breast cancer(see also kidney, lymphoma) (888) 669-6682
KiraxBonita Springs, FL
amrubicin CelgeneSummit, NJ
late-stage breast cancer (see also lung) (908) 673-9000
ARC-100 Archer BiosciencesNew York, NY
(see also brain, prostate, skin)
ARRY-380(HER2 inhibitor)
Array BioPharmaBoulder, CO
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
breast cancer (monotherapy)(see also colorectal, lung, multiple myeloma, stomach)--------------------------------------------------breast cancer (combination therapy)
(888) 669-6682
-------------------------------------------
(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 201210
BREAST CANCER
Product Name Sponsor Indication Development Status
Avastin®
bevacizumabGenentechSouth San Francisco, CA
adjuvant HER2-negative breast can-cer, adjuvant HER2-positive breast cancer, adjuvant triple negative breast cancer(see also brain, colorectal, lung, ovarian, other)
AZD8931(erbB kinase inhibitor)
AstraZenecaWilmington, DE
advanced breast cancer (combination therapy)(see also solid tumors)
(800) 236-9933
(lonaprisan)Bayer HealthCare PharmaceuticalsWayne, NJ
metastatic breast cancer
Cambridge, MA
(see also stomach)(617) 679-2000
BKM120 Novartis PharmaceuticalsEast Hanover, NJ
second-line breast cancer(see also brain, lung, other) (888) 669-6682
breast cancer vaccine (dendritic cell vaccine)
brostallicin Cell TherapeuticsSeattle, WA
triple-negative breast cancer
BTSCAN Molecular Targeting TechnologiesWest Chester, PA
breast cancer (diagnosis)(610) 738-7938
BZL-101 BionovoEmeryville, CA
cabozantinib ExelixisSouth San Francisco, CA
(see also kidney, lung, ovarian, prostate, other)
cancer vaccine MabVax TherapeuticsSan Diego, CA
(see also sarcoma)
CDX-011(glembatumumab vedotin)
Celldex TherapeuticsNeedham, MA
breast cancer (Fast Track)(see also skin)
CV-301(cancer vaccine) Mountain View, CA
metastatic breast cancer
D-1MT NewLink GeneticsAmes, IA
second-line metastatic breast cancer(see also solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 11
BREAST CANCER
Product Name Sponsor Indication Development Status
dalotuzumab MerckWhitehouse Station, NJ
second-line breast cancer (combination therapy)(see also lung, pancreatic, other)--------------------------------------------------
(800) 672-6372
-------------------------------------------
(800) 672-6372
DPX-0907Halifax, Canada
(see also ovarian, prostate)
eniluracil Adherex Technologies metastatic breast cancer(combination therapy)
entinostat Syndax PharmaceuticalsWaltham, MA
(see also colorectal, kidney, leukemia, lung, lymphoma)
etirinotecan pegol (NKTR-102)
Nektar TherapeuticsSan Francisco, CA
metastatic breast cancer(see also colorectal, ovarian, solid tumors)
EZN-2208 Enzon PharmaceuticalsPiscataway, NJ
metastatic breast cancer(see also colorectal, solid tumors)
Faslodex®
fulvestrantAstraZenecaWilmington, DE (800) 236-9933
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
(see also ovarian, other)
Folotyn®pralatrexate
Allos TherapeuticsWestminster, CO
(see also bladder, lung, lymphoma)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
ganitumab Amgen combination therapy(see also colorectal, lung, pancreatic, sarcoma)
GDC-0980
inhibitor)
GenentechSouth San Francisco, CA
hormone receptor-positive breast cancer(see also lymphoma, solid tumors)
immunotherapeutic)
GlaxoSmithKline neoadjuvant breast cancer
GVAX® Breast
cancer vaccineBioSante PharmaceuticalsLincolnshire, IL
Medicines in Development for Cancer
Medicines in Development Cancer 201212
BREAST CANCER
Product Name Sponsor Indication Development Status
immunotherapeuticGlaxoSmithKline
icrucumab Eli LillyIndianapolis, IN
Bridgewater, NJ
metastatic breast cancer(see also bladder, colorectal)
imetelstat GeronMenlo Park, CA
metastatic breast cancer(combination therapy)(see also leukemia, lung, multiple myeloma)
vaccine Doylestown, PA
(see also ovarian)
indibulinNew York, NY
late-stage breast cancer
iniparibBridgewater, NJ
neoadjuvant breast cancer(see also lung, ovarian)
Kyowa Hakko Kirin PharmaPrinceton, NJ breast cancer (609) 919-1100
LFA102(anti-prolactin receptor anti-body)
Novartis PharmaceuticalsEast Hanover, NJ
XOMABerkeley, CA
(see also prostate)(888) 669-6682
inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also skin)(888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
breast cancer (combination therapy)(see also colorectal, kidney, liver, lung)
liposome encapsulated paclitaxel (LEP-ETU) Phoenix, AZ (602) 910-2617
litronesib Eli LillyIndianapolis, IN
metastatic breast cancer(see also lung)
Lorus Therapeutics metastatic breast cancer(see also colorectal, kidney, leukemia, prostate)
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
breast cancer (diagnosis)(see also head/neck, skin)
application submitted
Medicines in Development for Cancer
Medicines in Development Cancer 2012 13
BREAST CANCER
Product Name Sponsor Indication Development Status
maraciclatide GE HealthcareWaukesha, WI
breast cancer (diagnosis) in clinical trialswww.gehealthcare.com
(notch signaling pathway inhibitor)
MerckWhitehouse Station, NJ
early-stage breast cancer, late-stage breast cancer(see also other)
(800) 672-6372
MK-2206(c-akt inhibitor)
MerckWhitehouse Station, NJ
HER2-positive breast cancer(see also other) (800) 672-6372
MM-111 Merrimack PharmaceuticalsCambridge, MA
breast cancer (combination therapy)
MM-302(anti-HER2 antibody doxorubicin conjugate)
Merrimack PharmaceuticalsCambridge, MA
motesanib Amgen (see also colorectal, lung, other)
MVA-BN® HER2
(HER-2/neu-based MVA vaccine)
Mountain View, CA
Myocet™doxorubicin liposomal
Sopherion TherapeuticsPrinceton, NJ (combination therapy) (Fast Track) (609) 986-2020
NeuVax™ Galena BiopharmaLake Oswego, OR
early-stage breast cancer(prevention of relapse)(see also prostate)
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also colorectal, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
nimotuzumab YM Biosciences USALehigh Valley, PA
(see also brain, prostate)
NK-012 Nippon Kayaku (see also lung)www.nipponkayaku.co.jp
OBP-301 Oncolys Biopharma (see also head/neck, liver, lung)www.oncolys.com
OncoGenex PharmaceuticalsBothell, WA
(see also lung, ovarian)
Medicines in Development for Cancer
Medicines in Development Cancer 201214
BREAST CANCER
Product Name Sponsor Indication Development Status
onartuzumab GenentechSouth San Francisco, CA
metastatic breast cancer (combination therapy)(see also colorectal, lung)
OPT-822/OPT-821 Optimer BiotechnologySan Diego, CA
PB-272 (neratinib) Puma BiotechnologyLos Angeles, CA
second-line breast cancer, neoadjuvant breast cancer
pertuzumab GenentechSouth San Francisco, CA
--------------------------------------------------second-line late-stage breast cancer
application submitted
-------------------------------------------
pertuzumab companion diagnostic
DakoGlostrup, Denmark
GenentechSouth San Francisco, CA
breast cancer (diagnostic)www.dako.com
pertuzumab companiondiagnostic(HercepTest™)
DakoGlostrup, Denmark
GenentechSouth San Francisco, CA
breast cancer (diagnosis)www.dako.com
pixantrone Cell TherapeuticsSeattle, WA
breast cancer (Fast Track)(see also lymphoma)
PTC299 PTC Therapeutics (see also solid tumors, other)(908) 222-7000
Quinamed® CephalonFrazer, PA
(see also ovarian, prostate)
ramucirumab Eli LillyIndianapolis, IN
Bridgewater, NJ
metastatic breast cancer(see also colorectal, stomach)
Reximmune-C®
personalized cancer vaccineEpeius BiotechnologiesSan Marino, CA
Rexin-G® Epeius BiotechnologiesSan Marino, CA
metastatic breast cancer(see also pancreatic, sarcoma)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 15
BREAST CANCER
Product Name Sponsor Indication Development Status
ridaforolimusCambridge, MA
MerckWhitehouse Station, NJ
metastatic breast cancer(see also kidney, lung, prostate, sarcoma, other)
(800) 672-6372
rucaparib Clovis OncologyBoulder, CO
(see also ovarian)
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also ovarian, prostate)
injectionEUSA PharmaLanghorne, PA
(see also multiple myeloma, prostate, sarcoma, other)
Bridgewater, NJ
Exelixis South San Francisco, CA
(see also other)
Bridgewater, NJ
Exelixis South San Francisco, CA
(see also lymphoma)
(MM-121)(anti-ErbB3 mAb)
Merrimack PharmaceuticalsCambridge, MA
Bridgewater, NJ
(see also lung, ovarian)
SF1 (sonodynamic therapy) SonneMedBoston, MA
advanced breast cancerwww.sonnemed.com
SPRYCEL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, pancreatic, prostate, other)
in clinical trials
Menlo Park, CA
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
(see also brain, head/neck, leukemia, liver, lung, other)
(631) 962-0600
tesetaxel GentaBerkeley Heights, NJ (see also bladder, prostate, skin,
stomach)(908) 286-9800
Medicines in Development for Cancer
Medicines in Development Cancer 201216
BREAST CANCER
Product Name Sponsor Indication Development Status
ThermoDox®
doxorubicin liposomalCelsionLawrenceville, NJ
recurrent breast cancer(see also colorectal, liver) (609) 896-9100
tigatuzumab Daiichi SankyoParsippany, NJ
(see also colorectal, liver, lymphoma, ovarian, pancreatic)
tivozanib Astellas Pharma US
AVEO PharmaceuticalsCambridge, MA
breast cancer (combination therapy)(see also colorectal, kidney)
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
metastatic breast cancer(see also kidney, multiple myeloma, prostate, skin, other)
(888) 669-6682
trabectedin Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
metastatic breast cancer (see also ovarian, prostate, sarcoma)
trastuzumab-DM1 GenentechSouth San Francisco, CA
trastuzumab-DM1 companion diagnostic(HercepTest™)
DakoGlostrup, Denmark
GenentechSouth San Francisco, CA
breast cancer (diagnosis)www.dako.com
trastuzumab-DM1 companion diagnostic
DakoGlostrup, Denmark
GenentechSouth San Francisco, CA
breast cancer (diagnosis)www.dako.com
(ENG protein inhibitor)TRACON PharmaceuticalsSan Diego, CA
(see also ovarian, prostate, other)
trebananib (AMG386)
Amgen (see also colorectal, kidney, liver, ovarian, stomach, other)
Tykerb®
lapatinibGlaxoSmithKline
(see also colorectal, head/neck, stomach)--------------------------------------------------
metastatic breast cancer--------------------------------------------------neoadjuvant breast cancer
application submitted
-------------------------------------------
-------------------------------------------
upamostat Munich, Germany www.wilex.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012 17
BREAST CANCER
Product Name Sponsor Indication Development Status
varlitinib ASLAN PharmaceuticalsSingapore www.aslanpharma.com
VeriStrat®
companion diagnostic testBiodesixBoulder, CO
advanced breast cancer (diagnosis-outcome test in HER2-overexpressing tumors)
(sepantronium)Astellas Pharma US (see also lymphoma)
Zolinza®
vorinostatMerckWhitehouse Station, NJ
(see also leukemia, lung, lymphoma, multiple myeloma, other) (800) 672-6273
Zytiga®
abirateroneJanssen BiotechHorsham, PA
second-line metastatic breast cancer(see also prostate)
CERVICAL CANCER
Product Name Sponsor Indication Development Status
ADXS-HPV AdvaxisPrinceton, NJ
cervical cancer, cervical intraepithelial neoplasia
PharmaMarMadrid, Spain
(see also sarcoma, other)www.pharmamar.com
PV701(replication-competent oncolytic virus)
Gaithersburg, MD
(see also colorectal)
terameprocol Erimos Pharmaceuticals cervical intraepithelial neoplasia (intravaginal)(see also brain, head/neck, solid tumors, other)
(HPV virus-like particle (VLP) vaccine)
MerckWhitehouse Station, NJ
prevention of cervical cancer, prevention of vulvovaginal cancer (800) 672-6372
(HPV vaccine)MerckWhitehouse Station, NJ
prevention of cervical cancer(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 201218
CERVICAL CANCER
Product Name Sponsor Indication Development Status
verpasep caltespen(cancer vaccine)
Akela Pharma cervical intraepithelial neoplasia
VGX-3100(DNA cancer vaccine) Blue Bell, PA
cervical intraepithelial neoplasia
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, lung, lymphoma, ovarian, prostate, skin, other)
Aptocine™ Light Sciences OncologyBellevue, WA
metastatic colorectal cancer
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
second-line colorectal cancer (combination therapy)(see also breast, lung, multiplemyeloma, stomach)
(888) 669-6682
Avastin®
bevacizumabGenentechSouth San Francisco, CA
metastatic colorectal cancer (treatment beyond progression) (see also brain, breast, lung, ovarian, other)
AVX701(CEA cancer immunotherapy)
AlphaVax colorectal cancer prevention in patients with advanced or metastatic CEA-expressing malignancies
belinostat Spectrum PharmaceuticalsHenderson, NV
colorectal cancer (combination therapy)(see also leukemia, liver, lung, lymphoma, ovarian, other)
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ
metastatic colorectal cancer(see also liver, sarcoma)
CPX-1 Celator PharmaceuticalsPrinceton, NJ
CT-011 CureTechYavne, Israel (combination therapy)
(see also leukemia, lymphoma)www.curetechbio.com
E7820 EisaiWoodcliff Lake, NJ
Medicines in Development for Cancer
Medicines in Development Cancer 2012 19
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
efatutazone Daiichi SankyoParsippany, NJ
metastatic colorectal cancer(see also lung, other)
EGEN-001 EGENHuntsville, AL
(see also ovarian, other)
EGFR antagonist companion diagnostic Valencia, CA
colorectal cancer (diagnosis) application submittedwww.qiagen.com
encapsulated cell therapy(macrobeads) New York, NY
refractory metastatic colorectal cancer(see also pancreatic, prostate)
entinostat Syndax PharmaceuticalsWaltham, MA
metastatic colorectal cancer(combination therapy)(see also breast, kidney, leukemia, lung, lymphoma)
ERBITUX®
cetuximabBristol-Myers SquibbPrinceton, NJ
Eli LillyIndianapolis, IN
(see also stomach)in clinical trials
etirinotecan pegol(NKTR-102)
Nektar TherapeuticsSan Francisco, CA
second-line colorectal cancer(see also breast, ovarian, solid tumors)
EZN-2208 Enzon PharmaceuticalsPiscataway, NJ
metastatic colorectal cancer(see also breast, solid tumors)
FANG™ Vaccine
autologous tumor cell vaccineGradalis (see also ovarian, skin)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
refractory, metastatic colorectal cancer(see also breast, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
ganitumab Amgen second-line metastatic colorectal cancer (combination therapy)(see also breast, lung, pancreatic, sarcoma)
(cancer vaccine) Louisville, CO
(see also lung, pancreatic)
Medicines in Development for Cancer
Medicines in Development Cancer 201220
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
GM-CT-01 Galectin TherapeuticsNewton, MA
colorectal cancer (combination therapy)
(monoclonal antibody)Gilead SciencesFoster City, CA
(see also pancreatic)
GVAX® Colorectal
cancer vaccineBioSante PharmaceuticalsLincolnshire, IL
icrucumab Eli LillyIndianapolis, IN
Bridgewater, NJ
(see also bladder, breast)
(TLR9 agonist) Cambridge, MA
(see also head/neck, lung)
Imprime PGG® BiotheraEagan, MN
(see also leukemia, lung, skin)
(pexastimogene devacirepvec)Jennerex BiotherapeuticsSan Francisco, CA
(see also liver)
KRN-330 Kyowa Hakko Kirin PharmaPrinceton, NJ
colorectal cancer (combination therapy)--------------------------------------------------colorectal cancer (monotherapy)
(609) 919-1100-------------------------------------------
(609) 919-1100
Morris Plains, NJ
labetuzumab-SN-38Morris Plains, NJ
LGX818(RAF inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
metastatic colorectal cancer(see also skin) (888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
second-line colorectal cancer(see also breast, kidney, liver, lung)
Lorus Therapeutics metastatic colorectal cancer(see also breast, kidney, leukemia, prostate)
motesanib Amgen (see also breast, lung, other)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 21
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
metastatic colorectal cancer (see also breast, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
NPC-1C(ensituximab)
Neogenix OncologyRockville, MD
metastatic colorectal cancer(see also pancreatic) (301) 917-6893
onartuzumab GenentechSouth San Francisco, CA
(see also breast, lung)
OncoVAX® VaccinogenFrederick, MD
(Fast Track)
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic colorectal cancer (combination therapy)(Fast Track)(see also brain, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
PHY906 PhytoCeutica (see also liver, pancreatic, cancer-related)
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also lung, ovarian, prostate)(206) 281-7001
polyclonal antibody stimulator Cancer AdvancesDurham, NC
(see also pancreatic, stomach)(919) 361-2162
PV701(replication-competent oncolytic virus)
Gaithersburg, MD
(see also cervical)
ramucirumab Eli LillyIndianapolis, IN
Bridgewater, NJ
(see also breast, stomach)
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
metastatic colorectal cancer (Fast Track)(see also kidney, lung, solid tumors, stomach)
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
(see also brain, head/neck, lung, ovarian, pancreatic, sarcoma,skin, solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 201222
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
RG7160(EGFR inhibitor)
RocheNutley, NJ
second-line metastatic colorectal cancer (combination therapy)
(EGFL7 inhibitor)GenentechSouth San Francisco, CA
(see also lung)
RIGScan™
monoclonal antibody targeting agent
Navidea BiopharmaceuticalsDublin, OH
metastatic colorectal cancer (diagnosis)
application submitted(800) 793-0079
robatumumab MerckWhitehouse Station, NJ
(see also sarcoma, solid tumors)(800) 672-6372
SymphogenLyngby, Denmark
metastatic colorectal cancerwww.symphogen.com
TAS-102 Taiho Pharma U.S.A.Princeton, NJ
telatinib ACT BiotechSan Francisco, CA
(see also stomach)
TF2(pretargeted radioimmuno-therapy)
Morris Plains, NJ
colorectal cancer
ThermoDox®
doxorubicin liposomalCelsionLawrenceville, NJ
adjuvant inoperable/unresectable, metastatic colorectal cancer(see also breast, liver)
(609) 896-9100
tigatuzumab Daiichi SankyoParsippany, NJ
(see also breast, liver, lymphoma, ovarian, pancreatic)
tivantinib (ARQ 197)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
(see also kidney, liver, lung, pancreatic, sarcoma, other)
tivozanib Astellas Pharma US
AVEO PharmaceuticalsCambridge, MA
colorectal cancer (combination therapy)(see also breast, kidney)
trebananib (AMG386)
Amgen (see also breast, kidney, liver, ovarian, stomach, other)
Tykerb®
lapatinibGlaxoSmithKline metastatic colorectal cancer
(see also breast, head/neck, stomach)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 23
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
Vectibix®
panitumumabAmgen
cancer (see also head/neck)
application submitted
Xeloda®
capecitabineGenentechSouth San Francisco, CA colorectal cancer
(combination therapy)(see also brain, liver, stomach)
application submitted
Zaltrap™ Regeneron Pharmaceuticals
Bridgewater, NJ
second-line metastatic colorectal cancer(see also prostate)
application submitted
Zelboraf®
vemurafenibGenentechSouth San Francisco, CA
PlexxikonBerkeley, CA
(see also brain, other)
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
(dalantercept)Acceleron PharmaCambridge, MA
(see also multiple myeloma)
afatinibPharmaceuticals
second-line head/neck cancer(see also breast, brain, lung)
Access Pharmaceuticals
EisaiWoodcliff Lake, NJ
(see also brain, liver, skin, solid tumors, stomach)
foretinib(GSK1363089)
GlaxoSmithKline (see also kidney, liver, lung)
GL-0810(Orphan Drug)
GliknikBaltimore, MD www.gliknik.com
GL-0817(Orphan Drug)
GliknikBaltimore, MD
(see also multiple myeloma)www.gliknik.com
HF-10 Takara BioShiga, Japan www.takara-bio.com
Medicines in Development for Cancer
Medicines in Development Cancer 201224
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
(TLR9 agonist) Cambridge, MA
second-line head and neck cancer(combination therapy)(see also colorectal, lung)
New York, NY
(Fast Track)
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
head and neck cancer (diagnosis)(see also breast, skin)
Multikine®
leukocyte interleukin(Orphan Drug)
Vienna, VA
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, colorectal, kidney, leukemia, liver, lung, multiple myeloma, ovarian, other)
OBP-301 Oncolys Biopharma (see also breast, liver, lung)www.oncolys.com
PX-866 OncothyreonSeattle, WA
head and neck cancer (combination therapy)(see also brain, lung, prostate)
(206) 801-2100
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
metastatic head and neck cancer (combination therapy)(see also brain, colorectal, lung, ovarian, pancreatic, sarcoma, skin, solid tumors)
(EGFR antagonist)GenentechSouth San Francisco, CA
seliciclib(CYC202)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
nasopharyngeal cancer (see also solid tumors)
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
(combination therapy)(see also brain, breast, leukemia,liver, lung, other)
(631) 962-0600
TAS-106 Taiho Pharma U.S.A.Princeton, NJ
Medicines in Development for Cancer
Medicines in Development Cancer 2012 25
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
terameprocol Erimos Pharmaceuticals head and neck cancer (intratumoral)(see also brain, cervical, solid tumors, other)
TNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
(see also prostate, skin, stomach)
Tykerb®
lapatinibGlaxoSmithKline head and neck squamous cell
carcinoma (resectable disease)(see also breast, colorectal, stomach)
(Orphan Drug)
Viventia BiotechnologiesMississauga, Canada
(Fast Track)(see also bladder)
Vectibix®
panitumumabAmgen
(see also colorectal)--------------------------------------------------second-line head and neck cancer
-------------------------------------------
KIDNEY CANCER
Product Name Sponsor Indication Development Status
®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
hepatocellular carcinoma(see also breast, lymphoma) (888) 669-6682
AGS-003(personalized dendritic cell vaccine)
Argos TherapeuticsDurham, NC
renal cancer (combination therapy)(Fast Track)--------------------------------------------------metastatic renal cancer (monotherapy)
(919) 287-6300-------------------------------------------
(919) 287-6300
AMG 172 Amgen
anti-PD1 Bristol-Myers SquibbPrinceton, NJ
renal cell carcinoma(see also lung, skin)
Bionomicswww.bionomics.com.au
cabozantinib ExelixisSouth San Francisco, CA
renal cell carcinoma(see also breast, lung, ovarian, prostate, other)
Medicines in Development for Cancer
Medicines in Development Cancer 201226
KIDNEY CANCER
Product Name Sponsor Indication Development Status
CVX 060
(Ang2 antagonist)New York, NY
renal cell carcinoma(see also solid tumors)
CYT107(interleukin-7)
CytherisRockville, MD
(see also skin)
entinostat Syndax PharmaceuticalsWaltham, MA
(see also breast, colorectal, leukemia, lung, lymphoma)
foretinib(GSK1363089)
GlaxoSmithKline (see also head/neck, liver, lung)
(cancer vaccine)immatics biotechnologies renal cancer
www.immatics.com
Inlyta®
axitinib(Orphan Drug)
New York, NY
advanced renal cell carcinoma in treatment-naive patients(see also liver, other)
Istodax®
romidepsinCelgeneSummit, NJ
renal cancer(see also pancreatic, prostate, other) (908) 673-9000
(panobinostat)Novartis PharmaceuticalsEast Hanover, NJ
renal cancer(see also leukemia, multiple myeloma, prostate, solid tumors)
(888) 669-6682
linifanib Abbott LaboratoriesAbbott Park, IL
renal cancer (see also breast, colorectal, liver, lung)
(Orphan Drug)
Lorus Therapeutics metastatic renal cancer(see also breast, colorectal, leukemia, prostate)
naptumomab estafenatox Active BiotechLund, Sweden
(see also lung, pancreatic)www.activebiotech.com
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
renal cell carcinoma (adjuvant therapy)(see also breast, colorectal, head/neck, leukemia, liver, lung, multiple myeloma, ovarian, other)
Oncophage®
vitespen(Orphan Drug)
AgenusLexington, MA
renal cell carcinoma (Fast Track)
(TORC1/TORC2 inhibitor) Farmingdale, NY
renal cancer(see also lymphoma) (631) 962-0600
Medicines in Development for Cancer
Medicines in Development Cancer 2012 27
KIDNEY CANCER
Product Name Sponsor Indication Development Status
perifosine AEterna ZentarisBasking Ridge, NJ
metastatic renal cancer(see also brain, colorectal, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
Redectane®
companion diagnosticMunich, Germany
renal cancer (diagnosis)www.wilex.de
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
renal cancer(see also colorectal, lung, solid tumors, stomach)
Rencarex®
girentuximab(Orphan Drug)
Munich, Germany
clear cell renal cell carcinoma(Fast Track) www.wilex.de
ridaforolimusCambridge, MA
MerckWhitehouse Station, NJ
(see also breast, lung, prostate, sarcoma, other) (800) 672-6372
(vorsetuzumab mafodotin)Seattle GeneticsBothell, WA
renal cancer(see also lymphoma)
Sutent®
sunitinib(Orphan Drug)
New York, NY
renal cell carcinoma (adjuvant therapy)
tivantinib (ARQ 197)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
(see also colorectal, liver, lung, pancreatic, sarcoma, other)
tivozanib Astellas Pharma US
AVEO PharmaceuticalsCambridge, MA
(see also breast, colorectal)
--------------------------------------------------renal cancer(combination therapy)
-------------------------------------------
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, multiple myeloma, prostate, skin, other) (888) 669-6682
Torisel®
temsirolimus(Orphan Drug)
New York, NY
renal cell carcinoma
trebananib (AMG386)
Amgen renal cancer(see also breast, colorectal, liver, ovarian, stomach, other)
Medicines in Development for Cancer
Medicines in Development Cancer 201228
KIDNEY CANCER
Product Name Sponsor Indication Development Status
(cellular immunotherapyvaccine)
TVAX BiomedicalLenexa, KS
renal cell carcinoma
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
(see also lung, skin)(323) 221-7818
Votrient™pazopanib
GlaxoSmithKline (see also ovarian, other)
LEUKEMIA
Product Name Sponsor Indication Development Status
Abiogen PharmaPisa, Italy
chronic myeloid leukemia (CML)www.abiogen.it
AC220(quizartinib)
Ambit BiosciencesSan Diego, CA
Astellas Pharma US
second-line and third-line acute myeloid leukemia (AML) (monotherapy)(see also solid tumors)--------------------------------------------------acute lymphocytic leukemia (ALL)
-------------------------------------------
(JAK2 inhibitor)Ambit BiosciencesSan Diego, CA
Adcetris™brentuximab vedotin
Millennium PharmaceuticalsCambridge, MA
Seattle GeneticsBothell, WA
(see also lymphoma)
Aegera TherapeuticsMontreal, Canada
AML(see also lymphoma)--------------------------------------------------chronic lymphocytic leukemia (CLL)
-------------------------------------------
Afecta PharmaceuticalsIrvine, CA
in clinical trials
Medicines in Development for Cancer
Medicines in Development Cancer 2012 29
LEUKEMIA
Product Name Sponsor Indication Development Status
Argos TherapeuticsDurham, NC
CLL(919) 287-6300
AldagenDurham, NC
ALXN6000(samalizumab)
Alexion Pharmaceuticals CLL(see also multiple myeloma)
aminopterin Syntrix BiosystemsAuburn, WA
ALL
anti-CD22/CD19 mAb-toxinconjugate
Abiogen PharmaPisa, Italy
ALLwww.abiogen.com
Arno TherapeuticsFlemington, NJ
CLL(see also lymphoma, multiple myeloma)
(862) 703-7170
AR-67 Arno TherapeuticsFlemington, NJ
myelodysplastic syndromes(see also brain, solid tumors) (862) 703-7170
Arranon®
nelarabine(Orphan Drug)
GlaxoSmithKline(see also lymphoma)--------------------------------------------------second-line ALL
(888) 669-6682-------------------------------------------
(888) 669-6682
(KSP inhibitor)Array BioPharmaBoulder, CO
AML(see also multiple myeloma, solid tumors)
Arzerra®
ofatumumab(Orphan Drug)
GlaxoSmithKline(see also lymphoma)
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
CLL(see also brain, lung, lymphoma, prostate, stomach)
Ascenta TherapeuticsMalvern, PA
DebiopharmLausanne, Switzerland
AML(see also lymphoma)
www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 201230
LEUKEMIA
Product Name Sponsor Indication Development Status
(CDK inhibitor)Astex PharmaceuticalsDublin, CA
CLL(see also lymphoma, multiple myeloma, solid tumors)
AT9283(aurora/Jak2 inhibitor)(Orphan Drug)
Astex PharmaceuticalsDublin, CA
AML(see also lymphoma, multiple myeloma, solid tumors)
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
second-line CLL (combination therapy) (908) 673-9000
AZD1208(Pim kinase inhibitor)
AstraZenecaWilmington, DE
AML(800) 236-9933
bafetinib(Orphan Drug)
CytRx Los Angeles, CA
second-line CLL (see also brain, prostate)--------------------------------------------------ALL, CML
-------------------------------------------
Bcl-2 inhibitor(ABT-199/GDC-0199)
Abbott LaboratoriesAbbott Park, IL
GenentechSouth San Francisco, CA
CLL(see also lymphoma)
belinostat Spectrum PharmaceuticalsHenderson, NV
AML(see also colorectal, liver, lung, lymphoma, ovarian, other)
(aurora kinase B inhibitor) PharmaceuticalsAML(see also solid tumors)
PharmaceuticalsCLL
bosutinibNew York, NY
previously treated CML application submitted
cenersen(Orphan Drug)
EleosOmaha, NE
AML
Ceplene®
histamine dihydrochloride injection(Orphan Drug)
EpiCept AML application submitted
Medicines in Development for Cancer
Medicines in Development Cancer 2012 31
LEUKEMIA
Product Name Sponsor Indication Development Status
CLL immunotherapeutic vaccine MaxCyteGaithersburg, MD
CLL
Clolar®
clofarabine injection (Orphan Drug)
GenzymeCambridge, MA
AML (adults)
CNDO-109(tumor activated NK cells)
Coronado BiosciencesBurlington, MA
AML(781) 238-6621
(cytarabine/daunorubicin)(Orphan Drug)
Celator PharmaceuticalsPrinceton, NJ
AML
CT-011 CureTechYavne, Israel
second-line AML (combination therapy)(see also colorectal, lymphoma)
www.curetechbio.com
Seoul, South Korea
AML
Dacogen®
decitabineEisaiWoodcliff Lake, NJ
AML
--------------------------------------------------pediatric AML
application submitted
-------------------------------------------
danusertib Nerviano Medical SciencesNerviano, Italy
CMLwww.nervianoms.com
DCC-2036 Deciphera PharmaceuticalsLawrence, KS
ALL, CML
--------------------------------------------------AML
-------------------------------------------
GenentechSouth San Francisco, CA
CLL(see also lymphoma)
DCDT-2980S GenentechSouth San Francisco, CA
recurrent CLL(see also lymphoma)
Elacyt™elacytarabine(Orphan Drug)
Clavis PharmaOslo, Norway
late-stage AML(Fast Track)--------------------------------------------------early-stage AML
www.clavispharma.com-------------------------------------------
www.clavispharma.com
Medicines in Development for Cancer
Medicines in Development Cancer 201232
LEUKEMIA
Product Name Sponsor Indication Development Status
elesclomol Synta PharmaceuticalsLexington, MA
AML(see also lung, ovarian)
entinostat Syndax PharmaceuticalsWaltham, MA
(see also breast, colorectal, kidney, lung, lymphoma)
epratuzumab(Orphan Drug) Morris Plains, NJ
UCBAtlanta, GA
ALL in children (combination therapy)(see also lymphoma)
forodesine(Orphan Drug)
BioCryst PharmaceuticalsDurham, NC
CLL(see also lymphoma)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
ALL, AML, CML(see also breast, colorectal, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach)--------------------------------------------------myelodysplastic syndromes
-------------------------------------------
GNKG-168 CLLwww.sbibiotech.jp
GRNVAC1(dendritic cell vaccine)
Argos TherapeuticsDurham, NC
GeronMenlo Park, CA
AML(see also prostate)
GS-1101 Gilead SciencesFoster City, CA
second-line CLL (see also lymphoma)
GSK2110183(protein kinase B inhibitor)
GlaxoSmithKline (see also multiple myeloma)
immunotherapeutic)
GlaxoSmithKline AML
GVAX® Leukemia
cancer vaccine(Orphan Drug)
BioSante PharmaceuticalsLincolnshire, IL
AML, CML
Actinium PharmaceuticalsNewark, NJ
AML
Medicines in Development for Cancer
Medicines in Development Cancer 2012 33
LEUKEMIA
Product Name Sponsor Indication Development Status
(lintuzumab Bi-213)Actinium PharmaceuticalsNewark, NJ
AML
(lintuzumab-gelonin conjugate)Targa TherapeuticsSan Diego, CA
AML, CML, myelodysplasticsyndromes
ibrutinib Janssen BiotechHorsham, PA
PharmacyclicsSunnyvale, CA
CLL(see also lymphoma, multiple myeloma)
imatinib sublingual Kedem PharmaceuticalsMesa, AZ
CML in clinical trials
imetelstat GeronMenlo Park, CA
CLL(see also breast, lung, multiple myeloma)
Imprime PGG® BiotheraEagan, MN
CLL(see also colorectal, lung, skin)
CytRxLos Angeles, CA
AML, myelodysplastic syndromes(see also solid tumors)
inotuzumab ozogamicinNew York, NY
ALL(see also lymphoma)
(recombinant immunotherapeutic vaccine)
MemgenSan Diego, CA
CLL (monotherapy)(see also lymphoma)--------------------------------------------------refractory metastatic CLL (combination therapy)
-------------------------------------------
(quisinostat)Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
myelodysplastic syndromes, metastatic leukemia(see also lymphoma)
JVRS-100(lipid-DNA complex vaccine)
Colby PharmaceuticalSan Jose, CA
KX2-391 Kinex PharmaceuticalsBuffalo, NY
AML in the elderly(see also prostate) (716) 898-8626
Medicines in Development for Cancer
Medicines in Development Cancer 201234
LEUKEMIA
Product Name Sponsor Indication Development Status
(panobinostat)Novartis PharmaceuticalsEast Hanover, NJ
ALL, AML, myelodysplastic syndromes(see also kidney, multiple myeloma, prostate, solid tumors)
(888) 669-6682
(erismodegib)Novartis PharmaceuticalsEast Hanover, NJ
CML (combination therapy)(see also pancreatic, solid tumors, skin)
(888) 669-6682
lestaurtinib(Orphan Drug)
CephalonFrazer, PA
AML
leukemia DNA vaccineBlue Bell, PA
University of SouthamptonSouthampton, United Kingdom
AML, CML
(activated T-cells)LentigenGaithersburg, MD
University of PennsylvaniaPhiladelphia, PA
ALL, B-cell prolymphocytic leukemia, CLL(see also lymphoma)
(Orphan Drug)
Lorus Therapeutics AML (combination therapy)(see also breast, colorectal, kidney, prostate)--------------------------------------------------CML, myelodysplastic syndromes
-------------------------------------------
lurbinectedin PharmaMarMadrid, Spain
(see also solid tumors)www.pharmamar.com
Marqibo®
vincristine liposomal(Orphan Drug)
Talon TherapeuticsSan Mateo, CA
relapsed or refractory Philadelphia chromosome-negative ALL (Fast Track)(see also lymphoma, skin, other)--------------------------------------------------ALL in the elderly (Fast Track)
application submitted
-------------------------------------------
milatuzumabMorris Plains, NJ
CLL (monotherapy)(see also lymphoma, multiple myeloma)
(dinaciclib)(Orphan Drug)
MerckWhitehouse Station, NJ
CLL(see also lymphoma) (800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 35
LEUKEMIA
Product Name Sponsor Indication Development Status
MerckWhitehouse Station, NJ
AML(see also solid tumors) (800) 672-6372
mocetinostat(MGCD0103, HDAC inhibitor)
MethylGeneMontreal, Canada
CLL(see also lymphoma, solid tumors)
Mozobil®
plerixaforGenzymeCambridge, MA
AML
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL (see also lung, lymphoma)
--------------------------------------------------CLL, lymphoid leukemia
-------------------------------------------
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
AML, myelodysplastic syndromes(see also breast, colorectal, head/neck, kidney, liver, lung, multiple myeloma, ovarian, other)
obatoclax(Orphan Drug)
CephalonFrazer, PA
CLL(see also lung, lymphoma, multiple myeloma)
obinutuzumabWeston, MA
GenentechSouth San Francisco, CA
(see also lymphoma)
Omapro™omacetaxine(Orphan Drug)
CephalonFrazer, PA
second-line CML(see also solid tumors)--------------------------------------------------AML, myelodysplastic syndromes
application submitted
-------------------------------------------
Onconova TherapeuticsNewtown, PA
ALL(see also lymphoma)
oral azacitidine(Orphan Drug)
CelgeneSummit, NJ
myelodysplastic syndromes(Fast Track) (see also lung, lymphoma, solid tumors)--------------------------------------------------AML, CML
(908) 673-9000
-------------------------------------------
(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201236
LEUKEMIA
Product Name Sponsor Indication Development Status
oral clofaribine GenzymeCambridge, MA
myelodysplastic syndromes
(Orphan Drug)
TdT-positive leukemia(210) 677-6000
OXiGENESouth San Francisco, CA
AML, myelodysplastic syndromes
perifosine AEterna ZentarisBasking Ridge, NJ
refractory metastatic CLL(see also brain, colorectal, kidney, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
(midostaurin)Novartis PharmaceuticalsEast Hanover, NJ
AML(888) 669-6682
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent or refractory AML(see also brain, lymphoma, solid tumors)
ponatinib(Orphan Drug) Cambridge, MA
Philadelphia-positive ALL, CML
--------------------------------------------------AML
-------------------------------------------
ProactaLa Jolla, CA
AML
Revlimid®
lenalidomide(Orphan Drug)
CelgeneSummit, NJ
CLL, myelodysplastic syndromes(see also lymphoma) (908) 673-9000
rigosertib(Orphan Drug)
Onconova TherapeuticsNewtown, PA
myelodysplastic syndromes (intravenous)(see also lymphoma, ovarian, pancreatic)--------------------------------------------------CLL
--------------------------------------------------AML
--------------------------------------------------myelodysplastic syndromes (oral)
-------------------------------------------
-------------------------------------------
-------------------------------------------
Medicines in Development for Cancer
Medicines in Development Cancer 2012 37
LEUKEMIA
Product Name Sponsor Indication Development Status
sapacitabine (CYC682)(Orphan Drug)
Cyclacel PharmaceuticalsBerkeley Heights, NJ (see also lung, solid tumors)
--------------------------------------------------CLL (combination therapy),myelodysplastic syndromes
-------------------------------------------
SB989 (pracinostat) Oakland, CA
myelodysplastic syndromes(see also solid tumors, other)
(pacritinib) Oakland, CA
myelodysplastic syndromes
--------------------------------------------------myeloid leukemia
-------------------------------------------
SF1126(Orphan Drug)
Semafore PharmaceuticalsIndianapolis, IN
CLL(see also multiple myeloma, solid tumors)
(DNMT inhibitor)Astex PharmaceuticalsDublin, CA
AML, myelodysplastic syndromes
(recombinant fusion protein)(Orphan Drug)
Stemline TherapeuticsNew York, NY
AML, myelodysplastic syndromes
tamibarotene(Orphan Drug)
CytRxLos Angeles, CA
acute promyelocytic leukemia (APL) (Fast Track)(see also lung)--------------------------------------------------APL (combination therapy)
-------------------------------------------
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
myelodysplastic syndromes(see also brain, breast, head/neck, liver, lung, other) (631) 962-0600
Tasigna®
nilotinib(Orphan Drug)
Novartis PharmaceuticalsEast Hanover, NJ
CML (adolescents and children), ALL (adolescents and children)(see also skin, stomach)
(888) 669-6682
Temodar®
temozolomideMerckWhitehouse Station, NJ
AML(see also lung) (800) 672-6372
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, multiple myeloma, pancreatic, sarcoma)
thiarabine Access Pharmaceuticals (see also lymphoma)
Medicines in Development for Cancer
Medicines in Development Cancer 201238
LEUKEMIA
Product Name Sponsor Indication Development Status
TL-32711(birinapant)
TetraLogic PharmaceuticalsMalvern, PA
AML(see also solid tumors) (610) 889-9900
tosedostat(Orphan Drug)
Chroma TherapeuticsOxon, United Kingdom
AMLwww.chromatherapeutics.com
trametinib GlaxoSmithKline relapsed or refractory leukemia(see also brain, lung, lymphoma, multiple myeloma, pancreatic, skin)
Treanda®
bendamustineCephalonFrazer, PA
ALL in children, AML in children(see also lymphoma, multiple myeloma)
treosulfan MedacWedel, Germany
ALL, AML, myelodysplastic syndromes www.medac.de
TRU-016(humanized anti-CD37 therapeutic)
Emergent BioSolutionsRockville, MD
CLL(see also lymphoma)
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
second-line T-cell prolymphocytic leukemia (see also lymphoma, other, cancer-related)
veltuzumab(Orphan Drug) Morris Plains, NJ
CLL(see also lymphoma)
Vidaza®
azacitidine(Orphan Drug)
CelgeneSummit, NJ
AML in the elderly(see also lymphoma) (908) 673-9000
vosaroxin(Orphan Drug)
Sunesis PharmaceuticalsSouth San Francisco, CA
second-line AML(Fast Track)(see also ovarian)--------------------------------------------------AML in the elderly
-------------------------------------------
XmAb® 5574
(MOR208, anti-CD19 mAb)MorphoSysPlanegg, Germany
XencorMonrovia, CA
recurrent CLLwww.morphosys.com
Zolinza®
vorinostatMerckWhitehouse Station, NJ
AML, myelodysplastic syndromes(see also breast, lung, lymphoma, multiple myeloma, other)
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012 39
LIVER CANCER
Product Name Sponsor Indication Development Status
ALN-VSP Alnylam PharmaceuticalsCambridge, MA
bavituximab Peregrine Pharmaceuticals (see also lung, pancreatic)
BAY 86-9766(MEK inhibitor)
Ardea BiosciencesSan Diego, CA
Bayer HealthCare PharmaceuticalsWayne, NJ
(combination therapy)(see also pancreatic)
belinostat Spectrum PharmaceuticalsHenderson, NV
inoperable/unresectable liver cancer(see also colorectal, leukemia, lung, lymphoma, ovarian, other)
Cambridge, MA
(see also lung)(617) 679-2000
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ liver cancer (TACE)
(see also colorectal, sarcoma)
cixutumumab Eli LillyIndianapolis, IN
Bridgewater, NJ
(see also lung)
darinaparsinNew York, NY
(see also lymphoma, multiple myeloma, solid tumors)
DC Bead®
doxorubicin-eluting beadsBayer HealthCare PharmaceuticalsWayne, NJ
BiocompatiblesSurrey, United Kingdom
EisaiWoodcliff Lake, NJ
(see also brain, head/neck, skin, solid tumors, stomach)
foretinib(GSK1363089)
GlaxoSmithKline (see also head/neck, kidney, lung)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also breast, colorectal, leukemia, lung, multiple myeloma, pancreatic, prostate, skin, stomach)
Inlyta®
axitinib New York, NY
(see also kidney, other)
irinotecan eluting beadsSurrey, United Kingdom
liver metastases from colorectal cancer www.biocompatibles.com
Medicines in Development for Cancer
Medicines in Development Cancer 201240
LIVER CANCER
Product Name Sponsor Indication Development Status
(pexastimogene devacirepvec)(Orphan Drug)
Jennerex BiotherapeuticsSan Francisco, CA
(see also colorectal)
lansoprazole (Orphan Drug)
Apricus BiosciencesSan Diego, CA
linifanib Abbott LaboratoriesAbbott Park, IL (see also breast, colorectal, kidney,
lung)
mapatumumab Human Genome SciencesRockville, MD
liver cancer (combination therapy)(see also lung, multiple myeloma)
MB07133(HepDirect HepB inhibitor)
Ligand PharmaceuticalsLa Jolla, CA
inoperable/unresectable liver cancer
melphalan drug delivery system Delcath SystemsNew York, NY
inoperable/unresectable liver cancer application submitted
Progen PharmaceuticalsQueensland, Australia
liver cancer (Fast Track)(see also skin) www.progen.com.au
Nexavar®
sorafenib(Orphan Drug)
Bayer HealthCare PharmaceuticalsWayne, NJ
heptocellular carcinoma (adjuvant therapy)(see also breast, colorectal, head/neck, kidney, leukemia, lung, multiple myeloma, ovarian, other)
NV-1020 CatherexPhiladelphia, PA
OBP-301 Oncolys Biopharma (see also breast, head/neck, lung)www.oncolys.com
PEG arginine deiminase Polaris PharmaceuticalsSan Diego, CA
hepatocellular carcinoma(see also prostate, skin, other)
PHY906 PhytoCeutica (see also colorectal, pancreatic, cancer-related)
PV-10(rose bengal sodium)(Orphan Drug)
Provectus Pharmaceuticals liver cancer, liver metastases(see also skin)
RG7686 RocheNutley, NJ
metastatic liver cancer(combination therapy)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 41
LIVER CANCER
Product Name Sponsor Indication Development Status
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
cancer (combination therapy)(see also brain, breast, head/neck, leukemia, lung, other)--------------------------------------------------second-line liver cancer (combination therapy)
(631) 962-0600
-------------------------------------------
(631) 962-0600
TGF-ß R1 inhibitor Eli LillyIndianapolis, IN
(see also brain)
ThermoDox®
doxorubicin liposomal(Orphan Drug)
CelsionLawrenceville, NJ cancer (Fast Track)
(see also breast, colorectal)(609) 896-9100
tigatuzumab Daiichi SankyoParsippany, NJ
(see also breast, colorectal, lymphoma, ovarian, pancreatic)
tivantinib (ARQ 197) ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
second-line liver cancer (see also colorectal, kidney, lung, pancreatic, sarcoma, other)--------------------------------------------------liver cancer (combination therapy)
------------------------------------------
trebananib (AMG386)
Amgen (see also breast, colorectal, kidney, ovarian, stomach, other)
Xeloda®
capecitabineGenentechSouth San Francisco, CA
biliary cancer (combination therapy)(see also brain, colorectal, stomach)
Zadaxin®
thymalfasin alfa 1(Orphan Drug)
SciClone PharmaceuticalsFoster City, CA
(see also skin)
Medicines in Development for Cancer
Medicines in Development Cancer 201242
LUNG CANCER
Product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ (NSCLC)
(see also bladder, breast, ovarian, pancreatic, skin)
application submitted(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
NSCLC(see also brain, breast, colorectal, lymphoma, ovarian, prostate, skin, other)
(pan-HER inhibitor)Ambit BiosciencesSan Diego, CA
NCSLC(see also brain, breast)
Actimid®
pomalidomideCelgeneSummit, NJ
small-cell lung cancer (SCLC)(see also lymphoma, multiple myeloma, pancreatic)
(908) 673-9000
afatinibPharmaceuticals (see also brain, breast, head/neck)
--------------------------------------------------second-line NSCLC (Fast Track)
-------------------------------------------
Alimta®
pemetrexedEli LillyIndianapolis, IN
AMG888/U3-1287(anti-HER3 antibody)
Amgen
Daiichi SankyoParsippany, NJ
NSCLC
amrubicin(Orphan Drug)
CelgeneSummit, NJ
SCLC (Fast Track)(see also breast)--------------------------------------------------
(908) 673-9000-------------------------------------------
(908) 673-9000
amuvatinib Astex PharmaceuticalsDublin, CA
SCLC (combination therapy)(see also lymphoma)
anti-PD1 Bristol-Myers SquibbPrinceton, NJ
(see also kidney, skin)
AP26113Cambridge, MA
NSCLC
apricoxib(TG01)
Tragara PharmaceuticalsSan Diego, CA
second-line NSCLC (combination therapy)(see also pancreatic)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 43
LUNG CANCER
Product Name Sponsor Indication Development Status
astuprotimut-R
cancer immunotherapeutic)
GlaxoSmithKline adjuvant NSCLC (see also skin)
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
NSCLC (combination therapy), SCLC (combination therapy) (see also brain, leukemia, lymphoma, prostate, stomach)
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
third-line NSCLC(see also breast, colorectal, multiple myeloma, stomach)--------------------------------------------------second-line late-stage NSCLC(combination therapy)
(888) 669-6682
-------------------------------------------
(888) 669-6682
Avastin®
bevacizumabGenentechSouth San Francisco, CA
adjuvant NSCLC (see also brain, breast, colorectal, ovarian, other)
bavituximab Peregrine Pharmaceuticalssecond-line NSCLC(see also liver, pancreatic)
belinostat Spectrum PharmaceuticalsHenderson, NV
mesothelioma(see also colorectal, leukemia, liver, lymphoma, ovarian, other)--------------------------------------------------NSCLC
--------------------------------------------------SCLC
-------------------------------------------
-------------------------------------------
Cambridge, MA
NSCLC(see also liver) (617) 679-2000
BKM120 Novartis PharmaceuticalsEast Hanover, NJ
late-stage NSCLC (see also brain, breast, other) (888) 669-6682
cabozantinib ExelixisSouth San Francisco, CA
NSCLC(see also breast, kidney, ovarian, prostate, other)
(peptide mimetic)CanBasShizouka, Japan
mesothelioma (combination therapy),
therapy)(see also solid tumors)
www.canbas.co.jp
Medicines in Development for Cancer
Medicines in Development Cancer 201244
LUNG CANCER
Product Name Sponsor Indication Development Status
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
NSCLC(see also lymphoma, multiple myeloma)
(908) 673-9000
CEP-9722(PARP inhibitor)
CephalonFrazer, PA
NSCLC (combination therapy)(see also lymphoma)
Chk1 inhibitor(LY2603618)
Eli LillyIndianapolis, IN
NSCLC(see also pancreatic)
cixutumumab Eli LillyIndianapolis, IN
Bridgewater, NJ
NSCLC(see also liver)
Novelos TherapeuticsMadison, WI
NSCLC (diagnosis)
Novelos TherapeuticsMadison, WI
NSCLC (diagnosis)
CO-1686(EGFR inhibitor)
Clovis OncologyBoulder, CO
second-line NSCLC
custirsen(OGX-001/TV-1011)
OncoGenex PharmaceuticalsBothell, WA
Teva Pharmaceuticals(see also prostate)
dacomitinibNew York, NY
NSCLC(see also solid tumors)
dalotuzumab MerckWhitehouse Station, NJ
recurrent NSCLC (combination therapy)(see also breast, pancreatic, other)
(800) 672-6372
EC20(technetium Tc-99m etarfolatide)
EndocyteWest Lafayette, IN
NSCLC (diagnosis)(see also ovarian) www.endocyte.com
(vintafolide)EndocyteWest Lafayette, IN
MerckWhitehouse Station, NJ
NSCLC(see also ovarian) www.endocyte.com
(800) 672-6372
efatutazone Daiichi SankyoParsippany, NJ
NSCLC(see also colorectal, other)
elesclomol Synta PharmaceuticalsLexington, MA
NSCLC(see also leukemia, ovarian)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 45
LUNG CANCER
Product Name Sponsor Indication Development Status
emepepimut-S EMD SeronoRockland, MA
OncothyreonSeattle, WA
NSCLC (Fast Track)(see also prostate) (800) 283-8088
entinostat Syndax PharmaceuticalsWaltham, MA
NSCLC (combination therapy)(see also breast, colorectal, kidney, leukemia, lymphoma)
(AV-299)AVEO PharmaceuticalsCambridge, MA
NSCLC (combination therapy)(see also solid tumors)
Folotyn®
pralatrexateAllos TherapeuticsWestminster, CO
NSCLC(see also bladder, breast, lymphoma)
foretinib(GSK1363089)
GlaxoSmithKline NSCLC (see also head/neck, kidney, liver)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line NSCLC (combination therapy)(see also breast, colorectal, leukemia, liver, multiple myeloma, pancreatic, prostate, skin, stomach)--------------------------------------------------SCLC
-------------------------------------------
ganitumab Amgen(see also breast, colorectal, pancreatic, sarcoma)
(cancer vaccine) Louisville, CO
NSCLC(see also colorectal, pancreatic)
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
NSCLC (combination therapy)(see also prostate, skin, other) (888) 669-6682
(BRaf protein kinase inhibitor)GlaxoSmithKline BRAF mutation-positive disease
NSCLC(see also brain, skin)
Halaven®
eribulinEisaiWoodcliff Lake, NJ
NSCLC(see also prostate, sarcoma)
HS-110(cancer vaccine)
Heat BiologicsChapel Hill, NC
late-stage NSCLC (combination therapy)
Medicines in Development for Cancer
Medicines in Development Cancer 201246
LUNG CANCER
Product Name Sponsor Indication Development Status
HyperAcute® Lung
lung cancer immunotherapyNewLink GeneticsAmes, IA
metastatic NSCLC
(multi-epitope cancer vaccine)Biotech SynergySan Diego, CA
NSCLC
imetelstat GeronMenlo Park, CA
late-stage NSCLC(see also breast, leukemia, multiple myeloma)
(TLR9 agonist) Cambridge, MA
(see also colorectal, head/neck)
Imprime PGG® BiotheraEagan, MN
NSCLC(see also colorectal, leukemia, skin)
iniparibBridgewater, NJ
squamous NSCLC(see also breast, ovarian)--------------------------------------------------non-squamous NSCLC
-------------------------------------------
Iressa® AstraZenecaWilmington, DE NSCLC (800) 236-9933
RxCarlsbad, CA
late-stage NSCLC (combination therapy)(see also prostate)
(Hdm2 inhibitor)Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
NSCLC(see also prostate, solid tumors)
Karenitecin® BioNumerik Pharmaceuticals NSCLC(see also ovarian, solid tumors)
KD019 Kadmon PharmaceuticalsWarrendale, PA
late-stage NSCLC
KD032(ras/mTOR inhibitor)
Kadmon PharmaceuticalsWarrendale, PA
NSCLC(see also pancreatic)
linifanib Abbott LaboratoriesAbbott Park, IL
NSCLC(see also breast, colorectal, kidney, liver)
litronesib Eli LillyIndianapolis, IN
NSCLC(see also breast)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 47
LUNG CANCER
Product Name Sponsor Indication Development Status
lorvotuzumab mertansine
(Orphan Drug)
Waltham, MA
SCLC(see also multiple myeloma)
Lucanix®
belagenpumatucel-LNovaRxSan Diego, CA
NSCLC (Fast Track)(see also brain)
mapatumumab Human Genome SciencesRockville, MD
NSCLC (combination therapy)(see also liver, multiple myeloma)
(anti-PDGFR-alpha mAb)AstraZenecaWilmington, DE
Gaithersburg, MD
NSCLC(see also brain) (800) 236-9933
(301) 398-0000
(multi-kinase inhibitor)MethylGeneMontreal, Canada
NSCLC (combination therapy)
MORAb-003(farletuzumab)
EisaiWoodcliff Lake, NJ
NSCLC(see also ovarian)
MORAb-009(amatuximab)
EisaiWoodcliff Lake, NJ
mesothelioma
motesanib Amgen NSCLC(see also breast, colorectal, other)
naptumomab estafenatox Active BiotechLund, Sweden
NSCLC (Fast Track)(see also kidney, pancreatic) www.activebiotech.com
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL
NSCLC, SCLC(see also leukemia, lymphoma)
necitumumab Bristol-Myers SquibbPrinceton, NJ
Eli LillyIndianapolis, IN
Bridgewater, NJ
NSCLC
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
NSCLC(see also breast, colorectal, head/neck, kidney, leukemia, liver, multiple myeloma, ovarian, other)
Medicines in Development for Cancer
Medicines in Development Cancer 201248
LUNG CANCER
Product Name Sponsor Indication Development Status
NGR-hTNF(Orphan Drug)
MolMedMilan, Italy
second-line mesothelioma www.molmed.com
NK-012 Nippon Kayaku SCLC(see also breast) www.nipponkayaku.co.jp
NTX-010 NeotropixMalvern, PA
SCLC(see also other) www.neotropix.com
obatoclax CephalonFrazer, PA (see also leukemia, lymphoma,
multiple myeloma)
OBP-301 Oncolys Biopharma mesothelioma(see also breast, head/neck, liver) www.oncolys.com
OncoGenex PharmaceuticalsBothell, WA
NSCLC(see also breast, ovarian)
ombrabulin (AVE8062) Bridgewater, NJ (see also ovarian, sarcoma)
onartuzumab GenentechSouth San Francisco, CA
metastatic NSCLC(see also breast, colorectal)
Oncoprex™(TUSC2/FUS1 gene therapy)
Genprex NSCLC
Opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
NSCLC(see also brain, ovarian, stomach, other)
oral azacitidine CelgeneSummit, NJ
NSCLC(see also leukemia, lymphoma, solid tumors)
(908) 673-9000
inhibitor)Farmingdale, NY
NSCLC(see also ovarian, other) (631) 962-0600
Bryan OncorSomerville, MA
NSCLC, SCLC
palifosfamideNew York, NY
SCLC(see also sarcoma, solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 49
LUNG CANCER
Product Name Sponsor Indication Development Status
pegdinetanib (VEGFR-2 adnectin)
Bristol-Myers SquibbPrinceton, NJ
NSCLC
perifosine AEterna ZentarisBasking Ridge, NJ
NSCLC(see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)
picoplatin(Orphan Drug)
Ponaird PharmaceuticalsSeattle, WA
second-line SCLC(Fast Track)(see also colorectal, ovarian, prostate)
(206) 281-7001
plinabulin Nereus PharmaceuticalsSan Diego, CA
NSCLC
immunotherapeutic (recombinant)
GlaxoSmithKline NSCLC(see also skin)
PT107(allogeneic tumor cell vaccine)
Pique TherapeuticsDurham, NC
NSCLC
PX-866 OncothyreonSeattle, WA
NSCLC (combination therapy)(see also brain, head/neck, prostate) (206) 801-2100
ranpirnase Tamir BiotechnologyMonmouth Junction, NJ
NSCLC(732) 823-1003
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
NSCLC(see also colorectal, kidney, solid tumors, stomach)
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
NSCLC (combination therapy)(see also brain, colorectal, head/neck, ovarian, pancreatic, sarcoma, skin, solid tumors)
retaspimycinCambridge, MA
NSCLC
(EGFL7 inhibitor)GenentechSouth San Francisco, CA
NSCLC(see also colorectal)
Medicines in Development for Cancer
Medicines in Development Cancer 201250
LUNG CANCER
Product Name Sponsor Indication Development Status
(antibody drug conjugate)GenentechSouth San Francisco, CA
NSCLC(see also ovarian)
ridaforolimusCambridge, MA
MerckWhitehouse Station, NJ
NSCLC(see also breast, kidney, prostate, sarcoma, other)
(800) 672-6372
sapacitabine (CYC682)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
NSCLC(see also leukemia, solid tumors)
(anti-ErbB3 mAb)Merrimack PharmaceuticalsCambridge, MA
Bridgewater, NJ
NSCLC(see also breast, ovarian)
talactoferrin alfa (oral)(Orphan Drug)
AgennixPrinceton, NJ
NSCLC(Fast Track)
tamibarotene CytRxLos Angeles, CA
NSCLC(see also leukemia)
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
adjuvant NSCLC (see also brain, breast, head/neck, leukemia, liver, other) (631) 962-0600
Tavocept®
dimesnaBioNumerik Pharmaceuticals (see also cancer-related)
Tc-99m ethylenedicysteine glucosamine(EC-G)
Cell PointCentennial, CO
NSCLC (diagnosis)(303) 689-9693
Telcyta™canfosfamide
TelikPalo Alto, CA
third-line NSCLC (see also lymphoma, ovarian)
Temodar®
temozolomideMerckWhitehouse Station, NJ
SCLC(see also leukemia) (800) 672-6372
tivantinib (ARQ 197)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
NSCLC(see also colorectal, kidney, liver, pancreatic, sarcoma, other)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 51
LUNG CANCER
Product Name Sponsor Indication Development Status
topotecan liposomes injection Talon TherapeuticsSan Mateo, CA
SCLC(see also ovarian)
trametinib GlaxoSmithKline second-line NSCLC (see also leukemia, lymphoma, multiple myeloma, pancreatic, skin)
Vargatef™intedanib Pharmaceuticals
second-line late-stage NSCLC (combination therapy)(see also ovarian)
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
mesothelioma(see also kidney, skin) (323) 221-7818
volociximab Abbott LaboratoriesAbbott Park, IL
Weston, MA
NSCLC
Xalkori®
crizotinib(Orphan Drug)
New York, NY second-line ALK-positive NSCLC(see also solid tumors)--------------------------------------------------NSCLC (combination therapy)
-------------------------------------------
YERVOY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
NSCLC, SCLC(see also prostate, skin)
in clinical trials
Zolinza®
vorinostat(Orphan Drug)
MerckWhitehouse Station, NJ
mesothelioma(see also breast, leukemia, lymphoma, multiple myeloma, other)
(800) 672-6273
Zybrestat™fosbretabulin
OXiGENESouth San Francisco, CA (see also ovarian)
Medicines in Development for Cancer
Medicines in Development Cancer 201252
LYMPHOMA
Product Name Sponsor Indication Development Status
abexinostat(HDAC inhibitor)
PharmacyclicsSunnyvale, CA
lymphoma(see also sarcoma)
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, ovarian, prostate, skin, other)
Actimid®
pomalidomideCelgeneSummit, NJ (see also lung, multiple myeloma,
pancreatic)(908) 673-9000
Adcetris™brentuximab vedotin
Millennium PharmaceuticalsCambridge, MA
Seattle GeneticsBothell, WA
post-transplant Hodgkin’s lymphoma relapse prevention(see also leukemia)--------------------------------------------------relapsed/refractory CD30-positive non-Hodgkin’s lymphoma, relapsed/refractory anaplastic large-cell lymphoma--------------------------------------------------
lymphoma
-------------------------------------------
-------------------------------------------
Adcetris™ Companion Diagnostic
brentuximab vedotin companion diagnostic
Millennium PharmaceuticalsCambridge, MA
Seattle GeneticsBothell, WA
Ventana Medical Systems
cutaneous T-cell lymphoma (diagnosis), T-cell lymphoma (diagnosis)
in clinical trials(617) 679-7000
Aegera TherapeuticsMontreal, Canada
B-cell lymphoma(see also leukemia)
AEZS-112 AEterna Zentaris Basking Ridge, NJ
(see also solid tumors)
®
everolimusNovartis PharmaceuticalsEast Hanover, NJ
mantle cell lymphoma(see also breast, kidney) (888) 669-6682
AFM13Heidelberg, Germany
second-line Hodgkin’s disease
Alocrest™vinorelbine liposomal
Talon TherapeuticsSan Mateo, CA
non-Hodgkin’s lymphoma(see also solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 53
LYMPHOMA
Product Name Sponsor Indication Development Status
AME-133v (ocaratuzumab)
non-Hodgkin’s lymphoma
Amplimexon®
imexonAmpliMed second-line non-Hodgkin’s lymphoma
amuvatinib Astex PharmaceuticalsDublin, OH
(see also lung)
anti-CD22 mAb Abiogen PharmaPisa, Italy
B-cell lymphomawww.abiogen.com
Aplidin®
plitidepsinPharmaMarMadrid, Spain
(see also multiple myeloma, solid tumors) www.pharmamar.com
AR-12 Arno TherapeuticsFlemington, NJ
(see also solid tumors)(862) 703-7170
Arno TherapeuticsFlemington, NJ
(see also leukemia, multiple myeloma) (862) 703-7170
Arranon®
nelarabine(Orphan Drug)
GlaxoSmithKline(see also leukemia)--------------------------------------------------second-line T-cell lymphoma
(888) 669-6682-------------------------------------------
(888) 669-6682
Arzerra®
ofatumumabGlaxoSmithKline second-line diffuse large B-cell
lymphoma, second-line follicular lymphoma(see also leukemia)-------------------------------------------------- -------------------------------------------
ASP3026 Astellas Pharma US late-stage B-cell lymphoma(see also solid tumors)
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
non-Hodgkin’s lymphoma(see also brain, leukemia, lung, prostate, stomach)
Ascenta TherapeuticsMalvern, PA
DebiopharmLausanne, Switzerland
lymphoma (see also leukemia)
www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 201254
LYMPHOMA
Product Name Sponsor Indication Development Status
(CDK inhibitor)Astex PharmaceuticalsDublin, CA
mantle cell lymphoma(see also leukemia, multiple myeloma, solid tumors)
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
non-Hodgkin’s lymphoma(see also leukemia, multiple myeloma, solid tumors)
autologous cancer vaccineDusseldorf, Germany
Stellar BiotechnologiesPort Hueneme, CA
follicular lymphoma (prevention of relapse)
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
second-line non-Hodgkin’s - (908) 673-9000
Bcl-2 inhibitor(ABT-199/GDC-0199)
Abbott LaboratoriesAbbott Park, IL
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also leukemia)
belinostat(Orphan Drug)
Spectrum PharmaceuticalsHenderson, NV
peripheral T-cell lymphoma (PTCL) (Fast Track)(see also colorectal, leukemia, liver, lung, ovarian, other)
Bexxar®
tositumomab and iodine GlaxoSmithKline mantle cell lymphoma
(combination therapy)
BiovaxID®
B-cell lymphoma vaccine(personalized lymphoma vaccine)
indolent follicular lymphoma (Fast Track)--------------------------------------------------mantle cell lymphoma
-------------------------------------------
(kinase inhibitor)CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also multiple myeloma, solid tumors)
(908) 673-9000
CC-122 CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also multiple myeloma, solid tumors)
(908) 673-9000
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also lung, multiple myeloma) (908) 673-9000
CEP-9722(PARP inhibitor)
CephalonFrazer, PA
mantle cell lymphoma (combination therapy)(see also lung)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 55
LYMPHOMA
Product Name Sponsor Indication Development Status
Clearazide™mechlorethamine gel(Orphan Drug)
Ceptaris TherapeuticsMalvern, PA
cutaneous T-cell lymphoma(Fast Track)
application submitted
CT-011 CureTechYavne, Israel
diffuse large B-cell lymphoma, second-line follicular lymphoma (combination therapy)(see also colorectal, leukemia)
www.curetechbio.com
darinaparsin
(Orphan Drug)
New York, NY
second-line peripheral T-cell lymphoma(see also liver, multiple myeloma, solid tumors)--------------------------------------------------
(combination therapy), non-Hodgkin’s lymphoma
-------------------------------------------
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also leukemia)
DCDT-2980S GenentechSouth San Francisco, CA
recurrent non-Hodgkin’s lymphoma(see also leukemia)
Alopexx OncologyWaltham, MA
non-Hodgkin’s lymphoma
entinostat Syndax PharmaceuticalsWaltham, MA
Hodgkin’s disease(see also breast, colorectal, kidney, leukemia, lung)
enzastaurin Eli LillyIndianapolis, IN
diffuse large B-cell lymphoma
epratuzumab(Orphan Drug) Morris Plains, NJ
UCBAtlanta, GA
diffuse large B-cell lymphoma (combination therapy), follicular lymphoma (combination therapy)(see also leukemia)
epratuzumab Y-90Morris Plains, NJ
diffuse large B-cell lymphoma
--------------------------------------------------recurrent non-Hodgkin’s lymphoma
-------------------------------------------
Medicines in Development for Cancer
Medicines in Development Cancer 201256
LYMPHOMA
Product Name Sponsor Indication Development Status
EZN-2968 Enzon PharmaceuticalsPiscataway, NJ
(see also solid tumors)
Folotyn®
pralatrexate(Orphan Drug)
Allos TherapeuticsWestminster, CO
peripheral T-cell lymphoma
(see also bladder, breast, lung)--------------------------------------------------B-cell non-Hodgkin’s lymphoma, lymphoma (combination therapy)--------------------------------------------------cutaneous T-cell lymphoma
-------------------------------------------
-------------------------------------------
forodesine(Orphan Drug)
BioCryst PharmaceuticalsDurham, NC
cutaneous T-cell lymphoma(see also leukemia)
galiximabCambridge, MA
non-Hodgkin’s lymphoma(combination therapy)--------------------------------------------------
(monotherapy)
(617) 679-2000-------------------------------------------
(617) 679-2000
(small molecule)GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also solid tumors)
(ChK1 inhibitor)GenentechSouth San Francisco, CA
(see also solid tumors)
GenentechSouth San Francisco, CA
(see also solid tumors)
GDC-0917 GenentechSouth San Francisco, CA
(see also solid tumors)
GDC-0980
inhibitor)
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma(see also breast, solid tumors)
GS-1101 Gilead SciencesFoster City, CA
indolent non-Hodgkin’s lymphoma(see also leukemia)
(polio-like kinase inhibitor)GlaxoSmithKline non-Hodgkin’s lymphoma
(see also solid tumors)
GSK690693(AKT kinase inhibitor)
GlaxoSmithKline (see also solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 57
LYMPHOMA
Product Name Sponsor Indication Development Status
GlaxoSmithKline (see also solid tumors)
(protein kinase B inhibitor)GlaxoSmithKline (see also solid tumors)
iboctadekin GlaxoSmithKline non-Hodgkin’s lymphoma (combination therapy)(see also ovarian)
ibrutinib Janssen BiotechHorsham, PA
PharmacyclicsSunnyvale, CA
diffuse large B-cell lymphoma, mantle cell lymphoma(see also leukemia, multiple myeloma)
Waltham, MA
metastatic non-Hodgkin’s lymphoma
(mTOR inhibitor) La Jolla, CA (see also multiple myeloma, solid tumors)
inotuzumab ozogamicinNew York, NY
aggressive non-Hodgkin’s lymphoma(see also leukemia)--------------------------------------------------diffuse large B-cell lymphoma, indolent non-Hodgkin’s lymphoma
-------------------------------------------
interleukin-12 gene therapy OncoSec MedicalSan Diego, CA
cutaneous T-cell lymphoma(see also skin) www.oncosec.com
MemgenSan Diego, CA
follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma(see also leukemia)
(quisinostat)Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
cutaneous T-cell lymphoma(see also leukemia)
LEE011 Novartis PharmaceuticalsEast Hanover, NJ
(see also solid tumors)(888) 669-6682
(activated T-cells)LentigenGaithersburg, MD
University of PennsylvaniaPhiladelphia, PA
diffuse large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma(see also leukemia)
Medicines in Development for Cancer
Medicines in Development Cancer 201258
LYMPHOMA
Product Name Sponsor Indication Development Status
lucatumumab(HDC122)
Novartis PharmaceuticalsEast Hanover, NJ
XOMABerkeley, CA
lymphoma
--------------------------------------------------follicular lymphoma
(888) 669-6682-------------------------------------------
(888) 669-6682
Marqibo®
vincristine liposomalTalon TherapeuticsSan Mateo, CA
non-Hodgkin’s lymphoma(see also leukemia, skin, other)
milatuzumabMorris Plains, NJ
non-Hodgkin’s lymphoma(see also leukemia, multiple myeloma)
(dinaciclib)MerckWhitehouse Station, NJ
mantle cell lymphoma(see also leukemia) (800) 672-6372
MK-8808 MerckWhitehouse Station, NJ
late-stage follicular lymphoma (combination therapy) (800) 672-6372
MLN8237(alisertib)
Millennium PharmaceuticalsCambridge, MA
peripheral T-cell lymphoma (see also solid tumors)
MLN9708(ixazomib)
Millennium PharmaceuticalsCambridge, MA macroglobulinemia
(see also multiple myeloma, solid tumors)
mocetinostat(MGCD0103, HDAC inhibitor)(Orphan Drug)
MethylGeneMontreal, Canada
diffuse large B-cell lymphoma, follicular lymphoma(see also leukemia, solid tumors)
mogamulizumab(Orphan Drug)
Amgen cutaneous T-cell lymphoma, peripheral T-cell lymphoma
navitoclax(ABT-263)
Abbott LaboratoriesAbbott Park, IL
(see also leukemia, lung)
(marizomib)Nereus PharmaceuticalsSan Diego, CA
(see also multiple myeloma, solid tumors)
obatoclax(Orphan Drug)
CephalonFrazer, PA (combination therapy)
(see also leukemia, lung, multiple myeloma)--------------------------------------------------mantle cell lymphoma
-------------------------------------------
Medicines in Development for Cancer
Medicines in Development Cancer 2012 59
LYMPHOMA
Product Name Sponsor Indication Development Status
obinutuzumabWeston, MA
GenentechSouth San Francisco, CA
(combination therapy), second-line non-Hodgkin’s lymphoma (com-
lymphoma (combination therapy)(see also leukemia)--------------------------------------------------second-line non-Hodgkin’s lymphoma (monotherapy)
-------------------------------------------
Onconova TherapeuticsNewtown, PA
(see also leukemia)
ONO PharmaceuticalOsaka, Japan
B-cell lymphomawww.ono.co.jp
oral azacitidine CelgeneSummit, NJ
(see also leukemia, lung, solid tumors) (908) 673-9000
(TORC1/TORC2 inhibitor) Farmingdale, NY
(see also kidney)(631) 962-0600
P 27600 Piramal Life SciencesMumbai, India
mantle cell lymphomawww.piramallifesciences.com
perifosine AEterna ZentarisBasking Ridge, NJ
lymphoma (combination therapy),
(see also brain, colorectal, kidney, leukemia, lung, multiple myeloma, sarcoma, solid tumors, stomach)
Progen PharmaceuticalsQueensland, Australia
(see also solid tumors)www.progen-pharma.com
pixantrone Cell TherapeuticsSeattle, WA
diffuse large B-cell lymphoma (see also breast)
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
recurrent or refractory Hodgkin’s disease(see also brain, leukemia, solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 201260
LYMPHOMA
Product Name Sponsor Indication Development Status
Revlimid®
lenalidomideCelgeneSummit, NJ
non-Hodgkin’s lymphoma(see also leukemia) (908) 673-9000
RG7602 GenentechSouth San Francisco, CA
(see also solid tumors)
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, ovarian, pancreatic)
Rituxan®
rituxumab(fast infusion)
Weston, MA
GenentechSouth San Francisco, CA
non-Hodgkin’s lymphoma application submitted
Bridgewater, NJ
Exelixis South San Francisco, CA
non-Hodgkin’s lymphoma(see also breast)
(vorsetuzumab mafodotin)Seattle GeneticsBothell, WA
non-Hodgkin’s lymphoma(see also kidney)
Shape PharmaceuticalsCambridge, MA
cutaneous T-cell lymphomawww.shapepharma.com
sotrastaurin (AEB071)
Novartis PharmaceuticalsEast Hanover, NJ
diffuse large B-cell lymphoma(888) 669-6682
stem cell therapy Benitec BiopharmaSydney, Australia
City of Hope National Medical CenterDuarte, CA
www.benitec.com
teglarinad CephalonFrazer, PA
(see also solid tumors)
Telcyta™canfosfamide
TelikPalo Alto, CA
diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin’s lymphoma (see also lung, ovarian)
thiarabine Access Pharmaceuticals (see also leukemia)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 61
LYMPHOMA
Product Name Sponsor Indication Development Status
tigatuzumab Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, ovarian, pancreatic)
TKM-PLK1(RNAi)
Tekmira PharmaceuticalsBurnaby, Canada
(see also solid tumors)
trametinib GlaxoSmithKline (see also leukemia, lung, multiple myeloma, pancreatic, skin)
Treanda®
bendamustineCephalonFrazer, PA (combination therapy)
(see also leukemia, multiple myeloma)--------------------------------------------------second-line mantle cell lymphoma (combination therapy)
application submitted
-------------------------------------------
TRU-016(humanized anti-CD37 therapeutic)
Emergent BioSolutionsRockville, MD
non-Hodgkin’s lymphoma(see also leukemia)
Drais PharmaceuticalsBridgewater, NJ
(see also solid tumors)
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA (see also leukemia, cancer-related,
other)--------------------------------------------------non-Hodgkin’s B-cell lymphoma
--------------------------------------------------diffuse large B-cell lymphoma
-------------------------------------------
-------------------------------------------
veltuzumabMorris Plains, NJ
non-Hodgkin’s lymphoma(see also leukemia)
Vidaza®
azacitidineCelgeneSummit, NJ
(see also leukemia)(908) 673-9000
VTX-2337 VentiRx PharmaceuticalsSeattle, WA
B-cell lymphoma(see also solid tumors)--------------------------------------------------lymphoma
-------------------------------------------
Medicines in Development for Cancer
Medicines in Development Cancer 201262
LYMPHOMA
Product Name Sponsor Indication Development Status
XmAb®2513
(CD30-antigen inhibitor)XencorMonrovia, CA
Hodgkin’s disease, T-cell lymphoma
(sepantronium)Astellas Pharma US non-Hodgkin’s lymphoma
(see also breast)
zanolimumab(Orphan Drug)
Emergent BioSolutionsRockville, MD
cutaneous T-cell lymphoma
--------------------------------------------------peripheral T-cell lymphoma
-------------------------------------------
Zevalin®
ibritumomab tiuxetanSpectrum PharmaceuticalsHenderson, NV
second-line diffuse large B-cell lymphoma--------------------------------------------------mantle cell lymphoma
-------------------------------------------
Zolinza®
vorinostatMerckWhitehouse Station, NJ
B-cell lymphoma(see also breast, leukemia, lung, multiple myeloma, other)
(800) 672-6273
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
(dalantercept)Acceleron PharmaCambridge, MA
(see also head/neck)
Actimid®
pomalidomide(Orphan Drug)
CelgeneSummit, NJ
recurrent multiple myeloma(see also lung, lymphoma, pancreatic)
application submitted(908) 673-9000
(HDAC6 inhibitor)Acetylon PharmaceuticalsBoston, MA
ALXN6000(samalizumab)
Alexion Pharmaceuticals (see also leukemia)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 63
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
Aplidin®
plitidepsin(Orphan Drug)
PharmaMarMadrid, Spain
(see also lymphoma, solid tumors)www.pharmamar.com
Arno TherapeuticsFlemington, NJ
(see also leukemia, lymphoma)(862) 703-7170
(KSP inhibitor)Array BioPharmaBoulder, CO
multiple myeloma(see also leukemia, solid tumors)--------------------------------------------------multiple myeloma (combination therapy)
-------------------------------------------
(CDK inhibitor)Astex PharmaceuticalsDublin, CA
second-line multiple myeloma (see also leukemia, lymphoma, solid tumors)
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, solid tumors)
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, colorectal, lung, stomach) (888) 669-6682
BHQ880(mAb)
Novartis PharmaceuticalsEast Hanover, NJ
(see also solid tumors)(888) 669-6682
(Orphan Drug) Lund, Sweden
second-line late-stage multiple myeloma www.bioinvent.com
Kyowa Hakko Kirin PharmaPrinceton, NJ (609) 919-1100
(Orphan Drug)
Onyx PharmaceuticalsSouth San Francisco, CA
third-line multiple myeloma (Fast Track)(see also solid tumors)--------------------------------------------------multiple myeloma (combination therapy)
application submitted
-------------------------------------------
(noscapine)Cougar BiotechnologyRaritan, NJ www.cougarbiotechnology.com
(kinase inhibitor)CelgeneSummit, NJ
(see also lymphoma, solid tumors)(908) 673-9000
CC-122 CelgeneSummit, NJ
(see also lymphoma, solid tumors)(908) 673-9000
CC-223(mTOR inhibitor)
CelgeneSummit, NJ
(see also lung, lymphoma)(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201264
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
CP-18770(delanzomib)
CephalonFrazer, PA
(CK2 inhibitor)Cylene PharmaceuticalsSan Diego, CA
(see also solid tumors)
daratumumab GenmabPrinceton, NJ
darinaparsinNew York, NY
(see also liver, lymphoma, solid tumors)
GenentechSouth San Francisco, CA
refractory metastatic multiple myeloma
elotuzumab (BMS-901608)
Bristol-Myers SquibbPrinceton, NJ
ENMD-2076(Orphan Drug)
EntreMedRockville, MD
relapsed or refractory multiple myeloma(see also ovarian, other)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line multiple myeloma(see also breast, colorectal, leukemia, liver, lung, pancreatic, prostate, skin, stomach)
GL-0817 GliknikBaltimore, MD
(see also head/neck)www.gliknik.com
GSK2110183(protein kinase B inhibitor)
GlaxoSmithKline (see also leukemia)
GVAX® Myeloma
cancer vaccineBioSante PharmaceuticalsLincolnshire, IL
ibrutinib Janssen BiotechHorsham, PA
PharmacyclicsSunnyvale, CA
(see also leukemia, lymphoma)
imetelstat GeronMenlo Park, CA
second-line multiple myeloma (monotherapy)(see also breast, leukemia, lung)
indatuximab ravtansine(Orphan Drug)
BiotestDreieich, Germany
relapsed or refractory multiple myeloma www.biotest.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012 65
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
(mTOR inhibitor) La Jolla, CA
(see also lymphoma, solid tumors)
Marseille, France
multiple myeloma (monotherapy)
--------------------------------------------------multiple myeloma (combination therapy)
www.innate-pharma.com-------------------------------------------
www.innate-pharma.com
Kyowa Hakko Kirin PharmaPrinceton, NJ
multiple myeloma (combination therapy) (609) 919-1100
(panobinostat)Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, prostate, solid tumors) (888) 669-6682
lorvotuzumab mertansineWaltham, MA
(see also lung)
mapatumumab Human Genome SciencesRockville, MD
multiple myeloma (combination therapy)(see also liver, lung)
melphalan intravenous(captisol-enabled)(Orphan Drug)
CyDex PharmaceuticalsLenexa, KS www.ligand.com/cydex
milatuzumabMorris Plains, NJ
recurrent multiple myeloma(see also leukemia, lymphoma)
MLN9708(ixazomib)
Millennium PharmaceuticalsCambridge, MA
newly diagnosed multiple myeloma (combination therapy), second-line multiple myeloma(see also lymphoma, solid tumors)
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, colorectal, head/neck, kidney, leukemia, liver, lung, ovarian, other)
(marizomib)Nereus PharmaceuticalsSan Diego, CA
(see also lymphoma, solid tumors)
obatoclax CephalonFrazer, PA
(see also leukemia, lung, lymphoma)
Medicines in Development for Cancer
Medicines in Development Cancer 201266
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
perifosine(Orphan Drug)
AEterna ZentarisBasking Ridge, NJ
recurrent multiple myeloma (combination therapy)(Fast Track)(see also brain, colorectal, kidney, leukemia, lung, lymphoma, sarcoma, solid tumors, stomach)
(MFGR-1877S)GenentechSouth San Francisco, CA
refractory metastatic multiple myeloma(see also solid tumors)
(antibody drug conjugate)GenentechSouth San Francisco, CA
injectionEUSA PharmaLanghorne, PA
(see also breast, prostate, sarcoma, other)
SF1126 Semafore PharmaceuticalsIndianapolis, IN
(see also leukemia, solid tumors)
siltuximab Janssen BiotechHorsham, PA
(see also prostate, other)
SNS01-T(nano-encapsulated gene therapy)(Orphan Drug)
Senesco TechnologiesBridgewater, NJ
second-line multiple myeloma
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, leukemia, pancreatic, sarcoma)
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, kidney, prostate, skin, other) (888) 669-6682
trametinib GlaxoSmithKline multiple myeloma (see also leukemia, lung, lymphoma, pancreatic, skin)
Treanda®
bendamustineCephalonFrazer, PA
second-line multiple myeloma (combination therapy)(see also leukemia, lymphoma)
Xgeva™denosumab
Amgen (see also cancer-related, other)
Zolinza®
vorinostat(Orphan Drug)
MerckWhitehouse Station, NJ
metastatic multiple myeloma(see also breast, leukemia, lung, lymphoma, other)
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012 67
OVARIAN CANCER
Product Name Sponsor Indication Development Status
Å6 Angstrom PharmaceuticalsSolana Beach, CA
(see also other)
abagovomab(anti-idiotype mAb vaccine)(Orphan Drug)
MenariniFlorence, Italy www.menarini.com
Abraxane®
albumin-bound paclitaxelCelgeneSummit, NJ
(see also bladder, breast, lung, pancreatic, skin) (908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, lymphoma, prostate, skin, other)
AE37 peptide vaccine Antigen ExpressWorcester, MA
(see also breast)
AEZS-108(Orphan Drug)
AEterna ZentarisBasking Ridge, NJ
(see also bladder, prostate, other)
Avastin®
bevacizumab(Orphan Drug)
GenentechSouth San Francisco, CA
relapsed, platinum-sensitive ovarian cancer(see also brain, breast, colorectal, lung, other)--------------------------------------------------
application submitted
-------------------------------------------
BC-819 (gene therapy)(Orphan Drug)
BioCancell TherapeuticsJerusalem, Israel
late-stage ovarian cancer(see also bladder, pancreatic) www.biocancell.com
belinostat Spectrum PharmaceuticalsHenderson, NV
late-stage ovarian cancer (combination therapy)(see also colorectal, leukemia, liver, lung, lymphoma, other)
cabozantinib ExelixisSouth San Francisco, CA
(see also breast, kidney, lung, prostate, other)
catumaxomab Fresenius Biotech North AmericaWaltham, MA
(see also other)www.fresenius-biotech.com
CVac™MUC-1 cancer vaccine
Prima BioMedSydney, Australia www.primabiomed.com.au
Medicines in Development for Cancer
Medicines in Development Cancer 201268
OVARIAN CANCER
Product Name Sponsor Indication Development Status
DCVax®-Ovarian
dendritic cell-based vaccineNorthwest BiotherapeuticsBethesda, MD
GenentechSouth San Francisco, CA
second-line ovarian cancer (see also other)
DPX-0907Halifax, Canada
(see also breast, prostate)
DPX-survivac cancer vaccineHalifax, Canada
(irofulven)EisaiWoodcliff Lake, NJ
(see also prostate, other)
EC20(technetium Tc-99m etarfolatide)
EndocyteWest Lafayette, IN
ovarian cancer (diagnosis)(see also lung) www.endocyte.com
(vintafolide)EndocyteWest Lafayette, IN
MerckWhitehouse Station, NJ
platinum-resistant ovarian cancer(see also lung) www.endocyte.com
(800) 672-6372
EGEN-001(Orphan Drug)
EGENHuntsville, AL
(see also colorectal, other)
elesclomol Synta PharmaceuticalsLexington, MA
(see also leukemia, lung)
ENMD-2076(Orphan Drug)
EntreMedRockville, MD
platinum-resistant ovarian cancer(see also multiple myeloma, other)
etirinotecan pegol (NKTR-102)(Orphan Drug)
Nektar TherapeuticsSan Francisco, CA
platinum-resistant ovarian cancer(see also breast, colorectal, solid tumors)
FANG™ Vaccine
autologous tumor cell vaccineGradalis adjuvant ovarian cancer
(see also colorectal, skin)
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
(see also breast, other)
iboctadekin GlaxoSmithKline (see also lymphoma)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 69
OVARIAN CANCER
Product Name Sponsor Indication Development Status
vaccine Doylestown, PA
(see also breast)
iniparibBridgewater, NJ
(see also breast, lung)
Karenitecin®
cositecanBioNumerik Pharmaceuticals advanced ovarian cancer
(see also lung, solid tumors)
KHK-2866 Kyowa Hakko Kirin PharmaPrinceton, NJ
ovarian cancer (combination therapy)(see also solid tumors) (609) 919-1100
MerckWhitehouse Station, NJ
second-line ovarian cancer (800) 672-6372
MORAb-003(farletuzumab)
EisaiWoodcliff Lake, NJ
platinum-sensitive ovarian cancer(see also lung)
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ (see also breast, colorectal,
head/neck, kidney, leukemia, liver, lung, multiple myeloma, other)
OncoGenex PharmaceuticalsBothell, WA
(see also breast, lung)
olaratumab(LY3012207)
Eli LillyIndianapolis, IN
Bridgewater, NJ
(see also brain)
ombrabulin (AVE8062) Bridgewater, NJ
second-line ovarian cancer(see also lung, sarcoma)
Opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
(see also brain, lung, stomach, other)
oregovomab(Orphan Drug)
Quest PharmaTechEdmonton, Canada
inhibitor)Farmingdale, NY
(see also lung, other)(631) 962-0600
OVax®
autologous cell vaccine(Orphan Drug)
AVAX TechnologiesPhiladelphia, PA
Medicines in Development for Cancer
Medicines in Development Cancer 201270
OVARIAN CANCER
Product Name Sponsor Indication Development Status
phenoxodiol Marshall EdwardsSan Diego, CA
second-line late-stage ovarian cancer (Fast Track)(see also prostate, other)
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also colorectal, lung, prostate)(206) 281-7001
Quinamed® CephalonFrazer, PA
(see also breast, prostate)
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
ovarian cancer (combination therapy)(see also brain, colorectal, head/neck, lung, pancreatic, sarcoma, skin, solid tumors)--------------------------------------------------ovarian cancer (monotherapy)
-------------------------------------------
GenentechSouth San Francisco, CA
(antibody drug conjugate)GenentechSouth San Francisco, CA
(see also lung)
RG7600(antibody drug conjugate)
GenentechSouth San Francisco, CA
platinum-resistant ovarian cancer(see also pancreatic)
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, lymphoma, pancreatic)
rucaparib Clovis OncologyBoulder, CO
(see also breast)
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, prostate)
(anti-ErbB3 mAb)Merrimack PharmaceuticalsCambridge, MA
Bridgewater, NJ
(see also breast, lung)
SG2000 SpirogenLondon, United Kingdom www.spirogen.com
squalamine(Orphan Drug)
OHR PharmaceuticalNew York, NY
resistant ovarian cancer
Telcyta™canfosfamide
TelikPalo Alto, CA
(see also lung, lymphoma)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 71
OVARIAN CANCER
Product Name Sponsor Indication Development Status
tigatuzumab Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, lymphoma, pancreatic)
topotecan liposomes injection Talon TherapeuticsSan Mateo, CA
(see also lung)
trabectedin(Orphan Drug)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
second-line ovarian cancer(see also breast, prostate, sarcoma)
(ENG protein inhibitor)TRACON PharmaceuticalsSan Diego, CA
(see also breast, prostate, other)
trebananib (AMG386)
Amgen (see also breast, colorectal, kidney, liver, stomach, other)
Vargatef™intedanib Pharmaceuticals (combination therapy)
(see also lung)
vosaroxin Sunesis PharmaceuticalsSouth San Francisco, CA
(see also leukemia)
Votrient™pazopanib
GlaxoSmithKline (see also kidney, other)
Zybrestat™fosbretabulin(Orphan Drug)
OXiGENESouth San Francisco, CA
(see also lung)
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxel(Orphan Drug)
CelgeneSummit, NJ
(see also bladder, breast, lung, ovarian, skin) (908) 673-9000
Actimid®
pomalidomideCelgeneSummit, NJ
(see also lung, lymphoma, multiple myeloma) (908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 201272
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
anti-MUC1 mAb Quest PharmaTechEdmonton, Canada
anti-PSCA mAb AgensysSanta Monica, CA
Astellas Pharma US
metastatic pancreatic cancer(combination therapy)
apricoxib(TG01)
Tragara PharmaceuticalsSan Diego, CA
pancreatic (combination therapy)(see also lung)
Archexin®
RX-0201(Orphan Drug)
Rexahn PharmaceuticalsRockville, MD
metastatic pancreatic cancer (combination therapy)
AgensysSanta Monica, CA
Seattle GeneticsBothell, WA
metastatic pancreatic cancer(see also prostate)
bavituximab Peregrine Pharmaceuticals(see also liver, lung)
BAY 86-9766(MEK inhibitor)
Ardea BiosciencesSan Diego, CA
Bayer HealthCare PharmaceuticalsWayne, NJ
(combination therapy)(see also liver)
BC-819 (gene therapy)(Orphan Drug)
BioCancell TherapeuticsJerusalem, Israel (combination therapy)
(Fast Track)(see also bladder, ovarian)
www.biocancell.com
Chk1 inhibitor(LY2603618)
Eli LillyIndianapolis, IN
(see also lung)
CO-101(lipid drug conjugate of gemcitabine)(Orphan Drug)
Clovis OncologyBoulder, CO cancer, second-line metastatic
pancreatic cancer
CO-101companion diagnostic
Clovis OncologyBoulder, CO
Ventana Medical Systems
pancreatic cancer (diagnosis) in clinical trials
(Orphan Drug)
Cornerstone PharmaceuticalsCranbury, NJ
combination therapy(see also other)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 73
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
CRS-207(cancer vaccine)
Aduro BioTechBerkeley, CA
metastatic pancreatic cancer(combination therapy)
dalotuzumab MerckWhitehouse Station, NJ
(see also breast, lung, other)(800) 672-6372
encapsulated cell therapy(macrobeads) New York, NY
refractory metastatic pancreatic cancer(see also colorectal, prostate)
FG-3019(connective tissue growth factor)
FibroGenSan Francisco, CA
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, prostate, skin, stomach)
ganitumab Amgen(combination therapy)(see also breast, colorectal, lung, sarcoma)
Louisville, CO
(see also colorectal, lung)
glufosfamide(Orphan Drug)
Eleison PharmaceuticalsPrinceton, NJ
pancreatic cancer (Fast Track)
(monoclonal antibody)Gilead SciencesFoster City, CA
(see also colorectal)
GV1001 (hTERT RNA vaccine)
KAEL-GemVaxSeoul, South Korea www.kaelgemvax.com
GVAX® Pancreatic
cancer vaccine(Orphan Drug)
BioSante PharmaceuticalsLincolnshire, IL
Aduro BioTechBerkeley, CA
HyperAcute® Pancreas
algenpantucel-L(Orphan Drug)
NewLink GeneticsAmes, IA
Châtenay-Malabry, France www.immutep.org
(Orphan Drug)
CytRxLos Angeles, CA
pancreatic ductal adenocarcinoma(see also sarcoma, solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 201274
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Istodax®
romidepsinCelgeneSummit, NJ
(see also kidney, prostate, other)(908) 673-9000
™ruxolitinib Wilmington, DE
(see also other)
KD032(ras/mTOR inhibitor)
Kadmon PharmaceuticalsWarrendale, PA
(see also lung)
(erismodegib)Novartis PharmaceuticalsEast Hanover, NJ
neoadjuvant pancreatic cancer(see also leukemia, solid tumors, skin)
(888) 669-6682
LE-DT(liposomal docetaxel) Phoenix, AZ (602) 910-2617
(low molecular weight heparin)Momenta PharmaceuticalsCambridge, MA
metastatic pancreatic cancer
masitinib AB Science USAShort Hills, NJ
(see also stomach)
MM-398(nanotherapeutic)(Orphan Drug)
Merrimack PharmaceuticalsCambridge, MA
metastatic pancreatic cancer
naptumomab estafenatox Active BiotechLund, Sweden
(see also kidney, lung)www.activebiotech.com
NPC-1C(ensituximab)(Orphan Drug)
Neogenix OncologyRockville, MD
late-stage, metastatic pancreatic cancer(see also colorectal)
(301) 917-6893
paclitaxel polymeric micelle formulation
Samyang BiopharmaceuticalsSeoul, South Korea
late-stage pancreatic cancerwww.samyangpharm.com
PancAtak™gene therapy
AdvantageneAuburndale, MA
PharmacyclicsSunnyvale, CA
metastatic pancreatic cancer (combination therapy)
PEGPH20(pegylated recombinant human hyaluronidase)
Halozyme TherapeuticsSan Diego, CA
Medicines in Development for Cancer
Medicines in Development Cancer 2012 75
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
PHY906 PhytoCeutica (see also colorectal, liver, cancer-related)
polyclonal antibody stimulator(Orphan Drug)
Cancer AdvancesDurham, NC
(see also colorectal, stomach)(919) 361-2162
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
pancreatic cancer (combination therapy)(see also brain, colorectal, head/neck, lung, ovarian, sarcoma, skin, solid tumors)
Rexin-G®
(Orphan Drug)
Epeius BiotechnologiesSan Marino, CA
metastatic pancreatic cancer(Fast Track)(see also breast, sarcoma)
RG7600(antibody drug conjugate)
GenentechSouth San Francisco, CA
platinum-resistant pancreatic cancer(see also ovarian)
rigosertib Onconova TherapeuticsNewtown, PA
(see also leukemia, lymphoma, ovarian)
RP101 RESprotectDresden, Germany www.resprotect.de
SecreFlo™synthetic human secretin
RepligenWaltham, MA
pancreatic cancer (diagnosis) Phase 0
SPRYCEL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, breast, prostate, other)
in clinical trials
TH-302 Threshold PharmaceuticalsSouth San Francisco, CA
(see also brain, leukemia, multiple myeloma, sarcoma)
tigatuzumab Daiichi SankyoParsippany, NJ
(see also breast, colorectal, liver, lymphoma, ovarian)
tivantinib (ARQ 197)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
(see also colorectal, kidney, liver, lung, sarcoma, other)
trametinib GlaxoSmithKline(see also leukemia, lung, lymphoma, multiple myeloma, skin)
uridine triacetate Gaithersburg, MD
(see also stomach)
Medicines in Development for Cancer
Medicines in Development Cancer 201276
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Virulizin® Lorus Therapeutics
Y-90 clivatuzumab(Orphan Drug) Morris Plains, NJ (Fast Track)
PROSTATE CANCER
Product Name Sponsor Indication Development Status
Cambridge, MA
prostate cancer (diagnosis)
(nab®-docetaxel)CelgeneSummit, NJ cancer (908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
(see also brain, breast, colorectal, lung, lymphoma, ovarian, skin, other)
AEZS-108 AEterna ZentarisBasking Ridge, NJ
(see also bladder, ovarian, other)
AgonOxPortland, OR (800) 979-7202
AP1903 Bellicum Pharmaceuticals (see also cancer-related)
Apatone®
ascorbic acid/menadione San Diego, CA
APC-100 Adamis PharmaceuticalsSan Diego, CA www.adamispharmaceuticals.
com
ARC-100 Archer BiosciencesNew York, NY
hormone-refractory prostate cancer(see also brain, breast, skin)
Aragon PharmaceuticalsSan Diego, CA
hormone-refractory prostate cancer
Medicines in Development for Cancer
Medicines in Development Cancer 2012 77
PROSTATE CANCER
Product Name Sponsor Indication Development Status
AgensysSanta Monica, CA
Seattle GeneticsBothell, WA
castration-resistant prostate cancer(see also pancreatic)
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
hormone-refractory prostate cancer (combination therapy)(see also brain, leukemia, lung, lymphoma, stomach)--------------------------------------------------hormone-sensitive prostate cancer
-------------------------------------------
(androgen receptor down-regulator)
AstraZenecaWilmington, DE (800) 236-9933
bafetinib CytRx Los Angeles, CA
second-line metastatic hormone-refractory prostate cancer(see also brain, leukemia)
BPX-101(dendritic cell vaccine)
Bellicum Pharmaceuticals
cabozantinib ExelixisSouth San Francisco, CA
castration-resistant prostate cancer (see also breast, kidney, lung, ovarian, other)
CBLC102(mepacrine)
Cleveland BioLabsBuffalo, NY
Moscow, Russia
hormone-refractory prostate cancer
CD1089 (seocalcitol)
Cougar BiotechnologyRaritan, NJ www.cougarbiotechnology.com
cilengitide EMD SeronoRockland, MA
(see also brain)(800) 283-8088
custirsen(OGX-011/TV-1011)
OncoGenex PharmaceuticalsBothell, WA
Teva Pharmaceuticals
-tion therapy), second-line hormone-refractory prostate cancer (combina-tion therapy) (Fast Track)(see also lung)
EUSA PharmaLanghorne, PA
DPX-0907Halifax, Canada
(see also breast, ovarian)
Medicines in Development for Cancer
Medicines in Development Cancer 201278
PROSTATE CANCER
Product Name Sponsor Indication Development Status
DSTP-3086S GenentechSouth San Francisco, CA
metastatic hormone-refractory prostate cancer
(irofulven)EisaiWoodcliff Lake, NJ
hormone-refractory prostate cancer(see also ovarian, other)
(anti-integrin mAb)EMD SeronoRockland, MA
metastatic castration-resistant prostate cancer (800) 283-8088
emepepimut-S EMD SeronoRockland, MA
OncothyreonSeattle, WA
newly-diagnosed prostate cancer(see also lung) (800) 283-8088
encapsulated cell therapy(macrobeads) New York, NY
refractory metastatic prostate cancer(see also colorectal, pancreatic)
enzalutamide(MDV3100)
Astellas Pharma
MedivationSan Francisco, CA
hormone-refractory prostate cancer(Fast Track)
EPO-806(patupilone)
Novartis PharmaceuticalsEast Hanover, NJ
(see also brain)(888) 669-6682
(antisense oligonucleotide)Enzon PharmaceuticalsPiscataway, NJ
Firmagon®
degarelixFerring PharmaceuticalsParsippany, NJ
3-month formulation
--------------------------------------------------neoadjuvant therapy
(973) 796-1600-------------------------------------------
(973) 796-1600
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
second-line hormone-refractory prostate cancer(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, skin, stomach)
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
hormone-refractory prostate cancer(see also lung, skin, other) (888) 669-6682
GRNVAC1(dendritic cell vaccine)
Argos TherapeuticsDurham, NC
GeronMenlo Park, CA
(see also leukemia)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 79
PROSTATE CANCER
Product Name Sponsor Indication Development Status
(selective estrogen receptoralpha agonist)
GTxsecond-line advanced prostate cancer
GVAX® Prostate
cancer vaccineBioSante PharmaceuticalsLincolnshire, IL
Aduro BioTechBerkeley, CA
(Fast Track)
Halaven®
eribulinEisaiWoodcliff Lake, NJ
(see also lung, sarcoma)
Harbor TherapeuticsSan Diego, CA
hormone-refractory prostate cancer
intetumumab Janssen BiotechHorsham, PA
(see also skin)
Santa Ana, CA www.io-therapeutics.com
RxCarlsbad, CA
prostate cancer (combination therapy)(see also lung)
Istodax®
romidepsinCelgeneSummit, NJ
(see also kidney, pancreatic, other)(908) 673-9000
(anti-PMSA mAb)BZL BiologicsNew York, NY
metastatic prostate cancer, non-metastatic prostate cancer
(Hdm2 inhibitor)Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
(see also lung, solid tumors)
KX2-391 Kinex PharmaceuticalsBuffalo, NY
(see also leukemia)(716) 898-8626
(panobinostat)Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, multiple myeloma, solid tumors) (888) 669-6682
LFA102(anti-prolactin receptor antibody)
Novartis PharmaceuticalsEast Hanover, NJ
XOMABerkeley, CA
(see also breast)(888) 669-6682
Lorus Therapeutics metastatic prostate cancer(see also breast, colorectal, kidney, leukemia)
Medicines in Development for Cancer
Medicines in Development Cancer 201280
PROSTATE CANCER
Product Name Sponsor Indication Development Status
(GnRH antagonist)Merrion PharmaceuticalsWilmington, DE
MVA-BN® PRO
antigen cancer vaccine Mountain View, CA
NeuVax™ Galena BiopharmaLake Oswego, OR
(see also breast)
nimotuzumab YM Biosciences USALehigh Valley, PA
(see also brain, breast)
NX-1207 Nymox PharmaceuticalQuebec, Canada (800) 936-9669
ODM-201(androgen receptor antagonist)
Endo PharmaceuticalsChadds Ford, PA
OrionEspoo, Finland
castration-resistant prostate cancer
oncolytic virus CZ BioMed
anti-idiotype cancer vaccine VaxOncoSeoul, South Korea www.vaxonco.com
Onyvax-P(prostate cancer vaccine)
VaxOncoSeoul, South Korea
ozarelix Spectrum PharmaceuticalsHenderson, NV
hormone-dependent prostate cancer
PEG arginine deiminase Polaris PharmaceuticalsSan Diego, CA
prostate cancer (combination therapy)(see also liver, skin, other)
phenoxodiol Marshall EdwardsSan Diego, CA
prostate cancer (Fast Track)(see also ovarian, other)
picoplatin Ponaird PharmaceuticalsSeattle, WA
(see also colorectal, lung, prostate)(206) 281-7001
ProstAtak™gene therapy
AdvantageneAuburndale, MA
adjuvant prostate cancer(Fast Track)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 81
PROSTATE CANCER
Product Name Sponsor Indication Development Status
prostate cancer vaccine(anti-GnRH)
Novartis Vaccines & DiagnosticsCambridge, MA
Pepscan TherapeuticsLelystad, Netherlands
(617) 871-7000
Prostvac™rilimogene galvacirepvec Mountain View, CA
castration-resistant prostate cancer(Fast Track)
Provenge®
sipuleucel-TDendreonSeattle, WA
recurrent early-stage prostate cancer
--------------------------------------------------neoadjuvant early-stage prostate cancer
-------------------------------------------
PRX-302 Sophiris BioLa Jolla, CA
PSMA ADC(anti-drug conjugate)
Progenics Pharmaceuticals
PSMA protein vaccine(recombinant soluble)
Progenics Pharmaceuticals
PSMA VRP therapeutic vaccine Progenics Pharmaceuticals
PX-866 OncothyreonSeattle, WA
hormone-refractory prostate cancer(see also brain, head/neck, lung) (206) 801-2100
Quinamed® CephalonFrazer, PA
(see also breast, ovarian)
Momotaro-GeneOkayama, Japan www.mt-gene.com
ridaforolimusCambridge, MA
MerckWhitehouse Station, NJ
(see also breast, kidney, lung, sarcoma, other) (800) 672-6372
sagopilone Bayer HealthCare PharmaceuticalsWayne, NJ
(see also breast, ovarian)
injectionEUSA PharmaLanghorne, PA
(see also breast, multiple myeloma, sarcoma, other)
siltuximab Janssen BiotechHorsham, PA
hormone-refractory prostate cancer(see also multiple myeloma, other)
Medicines in Development for Cancer
Medicines in Development Cancer 201282
PROSTATE CANCER
Product Name Sponsor Indication Development Status
SPRYCEL®
dasatinibBristol-Myers SquibbPrinceton, NJ
(see also brain, breast, pancreatic, other)
in clinical trials
Millennium PharmaceuticalsCambridge, MA
TAK-700 (orteronel)
Millennium PharmaceuticalsCambridge, MA (combination therapy), second-line
metastatic prostate cancer(combination therapy)--------------------------------------------------prostate cancer
-------------------------------------------
tasquinimod(TASQ)
Active BiotechLund, Sweden
metastatic prostate cancer
--------------------------------------------------second-line metastatic prostate cancer
www.activebiotech.com-------------------------------------------
www.activebiotech.com
TeloB-Vax
telomerase cancer vaccineAdamis PharmaceuticalsSan Diego, CA www.adamispharmaceuticals.
com
tesetaxel GentaBerkeley Heights, NJ
(see also bladder, breast, skin, stomach) (908) 286-9800
tigapotide Kotinos PharmaceuticalsNew York, NY
hormone-refractory prostate cancer
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
(see also breast, kidney, multiple myeloma, skin, other) (888) 669-6682
TNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
(see also head/neck, skin, stomach)
TOK-001 Tokai PharmaceuticalsCambridge, MA
castration-resistant prostate cancer
trabectedin Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
(see also breast, ovarian, sarcoma)
(ENG protein inhibitor)TRACON PharmaceuticalsSan Diego, CA
(see also breast, ovarian, other)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 83
PROSTATE CANCER
Product Name Sponsor Indication Development Status
Trofex™Cambridge, MA
prostate cancer (diagnosis)
TroVax®
tumor-associated antigen vaccine
Oxford BioMedicaOxford, United Kingdom
hormone-refractory prostate cancer(combination therapy) www.oxfordbiomedica.co.uk
Viamet PharmaceuticalsMorrisville, NC
YERVOY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
prostate cancer (post-hormonal therapy), prostate cancer (post-chemotherapy)(see also lung, skin)
in clinical trials
Zaltrap™ Regeneron Pharmaceuticals
Bridgewater, NJ
prostate cancer(see also colorectal)
Zytiga®
abirateroneJanssen BiotechHorsham, PA (see also breast)
--------------------------------------------------neoadjuvant prostate cancer
-------------------------------------------
SARCOMA
Product Name Sponsor Indication Development Status
United TherapeuticsSilver Spring, MD
soft tissue sarcoma(see also brain, other) (301) 608-9292
abexinostat(HDAC inhibitor)
PharmacyclicsSunnyvale, CA
sarcoma(see also lymphoma)
brivanib(VEGFR/FGFR kinase inhibitor)
Bristol-Myers SquibbPrinceton, NJ
(see also colorectal, liver)
cancer vaccine MabVax TherapeuticsSan Diego, CA
(see also breast)
ganitumab Amgen (see also breast, colorectal, lung, pancreatic)
Halaven®
eribulinEisaiWoodcliff Lake, NJ
(see also lung, prostate)
Medicines in Development for Cancer
Medicines in Development Cancer 201284
SARCOMA
Product Name Sponsor Indication Development Status
(Orphan Drug)
CytRxLos Angeles, CA
soft tissue sarcoma(see also pancreatic, solid tumors)
Junovan™mifamurtide(Orphan Drug)
Millennium PharmaceuticalsCambridge, MA
osteosarcoma
ombrabulin (AVE8062) Bridgewater, NJ
(see also lung, ovarian)
palifosfamide
(Orphan Drug)
New York, NY (combination therapy)(see also lung, solid tumors)--------------------------------------------------second-line soft tissue sarcoma (combination therapy)--------------------------------------------------soft tissue sarcoma (monotherapy)
-------------------------------------------
-------------------------------------------
perifosine AEterna ZentarisBasking Ridge, NJ
(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, solid tumors, stomach)
PharmaMarMadrid, Spain
Ewing’s sarcoma(see also cervical, other) www.pharmamar.com
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, skin, solid tumors)
Rexin-G®
(Orphan Drug)
Epeius BiotechnologiesSan Marino, CA
osteosarcoma(see also breast, pancreatic)--------------------------------------------------soft tissue sarcoma
-------------------------------------------
ridaforolimus(Orphan Drug) Cambridge, MA
MerckWhitehouse Station, NJ
metastatic sarcoma (Fast Track)(see also breast, kidney, lung, prostate, other)--------------------------------------------------sarcoma
application submitted(800) 672-6372
-------------------------------------------
(800) 672-6372
robatumumab MerckWhitehouse Station, NJ
osteosarcoma, sarcoma(see also colorectal, solid tumors) (800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 85
SARCOMA
Product Name Sponsor Indication Development Status
injectionEUSA PharmaLanghorne, PA
osteosarcoma(see also breast, multiple myeloma, prostate, other)
saridegib(Orphan Drug) Cambridge, MA
chondrosarcoma (inoperable/unresectable)
TH-302(Orphan Drug)
Threshold PharmaceuticalsSouth San Francisco, CA
soft tissue sarcoma(see also brain, leukemia, multiple myeloma, pancreatic)
tivantinib (ARQ 197)(Orphan Drug)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
soft tissue sarcoma(see also colorectal, kidney, liver, lung, pancreatic, other)
trabectedin(Orphan Drug)
Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
soft tissue sarcoma(see also breast, ovarian, prostate)--------------------------------------------------soft tissue sarcoma (adolescents and children)
-------------------------------------------
SKIN CANCER
Product Name Sponsor Indication Development Status
Abraxane®
albumin-bound paclitaxel(Orphan Drug)
CelgeneSummit, NJ
malignant melanoma(see also bladder, breast, lung, ovarian, pancreatic)
(908) 673-9000
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
malignant melanoma(see also brain, breast, colorectal, lung, lymphoma, ovarian, prostate, other)
New York, NY
malignant melanoma
Allovectin®
velimogene aliplasmid(Orphan Drug)
VicalSan Diego, CA
Medicines in Development for Cancer
Medicines in Development Cancer 201286
SKIN CANCER
Product Name Sponsor Indication Development Status
ALT-801 Altor BioScienceMiramar, FL
malignant melanoma(see also other)
anti-PD1 Bristol-Myers SquibbPrinceton, NJ
melanoma(see also kidney, lung)
APN301
fusion protein)
Apeiron BiologicsVienna, Austria
malignant melanoma(see also brain) www.apeiron-biologics.com
ARC-100 Archer BiosciencesNew York, NY
malignant melanoma (combination therapy)(see also brain, breast, prostate)
ARRY-162(MEK inhibitor)
Array BioPharmaBoulder, CO
malignant melanoma (BRAFV600E or NRAS mutations) (see also solid tumors)
astuprotimut-R
cancer immunotherapeutic)
GlaxoSmithKline malignant melanoma(see also lung)--------------------------------------------------inoperable/unresectable malignant melanoma
-------------------------------------------
autologous stem cell therapy California Stem CellsIrvine, CA
malignant melanoma
CytotechNatick, MA
basal cell cancer, squamous call cancer
Cavatak™coxsackievirus A21(Orphan Drug)
ViralyticsPymble, Australia
malignant melanomawww.viralytics.com
CB-10-01cancer vaccine
Cosmo PharmaceuticalsLainate, Italy
malignant melanomawww.cosmopharmaceuticals.com
CDX-011(glembatumumab vedotin)
Celldex TherapeuticsNeedham, MA
malignant melanoma(see also breast)
CYT107(interleukin-7)
CytherisRockville, MD
malignant melanoma(see also kidney)
New York, NY
malignant melanoma
GenentechSouth San Francisco, CA
malignant melanoma
Medicines in Development for Cancer
Medicines in Development Cancer 2012 87
SKIN CANCER
Product Name Sponsor Indication Development Status
dendritic cancer cell vaccine EMD MilliporeBillerica, MA
malignant melanoma
EisaiWoodcliff Lake, NJ
late-stage malignant melanoma(see also brain, head/neck, liver, solid tumors, stomach)
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
melanoma(see also brain, other)
ecromeximab Life Science Pharmaceuticals malignant melanoma (combination therapy)
Erivedge™vismodegib
GenentechSouth San Francisco, CA
early-stage basal cell cancer (resectable)
FANG™ Vaccine
autologous tumor cell vaccineGradalis malignant melanoma
(see also colorectal, ovarian)
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
malignant melanoma(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, stomach)
GDC-0973(MEK inhibitor)
GenentechSouth San Francisco, CA
second-line metastatic malignant melanoma (combination therapy) (see also solid tumors)
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also lung, prostate, other) (888) 669-6682
(BRaf protein kinase inhibitor)GlaxoSmithKline
stage malignant melanoma(see also brain, lung)
--------------------------------------------------BRAF mutation-positive metastatic malignant melanoma (combination therapy)
-------------------------------------------
(cancer vaccine)GlaxoSmithKline metastatic malignant melanoma
(cancer vaccine)GlaxoSmithKline
melanoma
Medicines in Development for Cancer
Medicines in Development Cancer 201288
SKIN CANCER
Product Name Sponsor Indication Development Status
HyperAcute® Melanoma
melanoma vaccineNewLink GeneticsAmes, IA
malignant melanoma
(cancer vaccine) Oxon, United Kingdom
malignant melanoma Phase 0www.immunocore.com
Imprime PGG® BiotheraEagan, MN
malignant melanoma(see also colorectal, leukemia, lung)
Wilmington, DE
malignant melanoma(see also solid tumors)
interleukin-12 gene therapy OncoSec MedicalSan Diego, CA
malignant melanoma, merkel cell carcinoma(see also lymphoma)
www.oncosec.com
intetumumab Janssen BiotechHorsham, PA
malignant melanoma(see also prostate)
(erismodegib)Novartis PharmaceuticalsEast Hanover, NJ
basal cell cancer(see also leukemia, pancreatic, solid tumors)
(888) 669-6682
inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also breast) (888) 669-6682
LGX818(RAF inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
metastatic malignant melanoma(see also colorectal) (888) 669-6682
Lymphoseek®
Tc-99m tilmanoceptNavidea PharmaceuticalsDublin, OH
malignant melanoma (diagnosis)(see also breast, head/neck)
application submitted
M-200 prophage cancer vaccine(vitespen)(Orphan Drug)
AgenusLexington, MA
metastatic melanoma(Fast Track)
Marqibo®
vincristine liposomal(Orphan Drug)
Talon TherapeuticsSan Mateo, CA
malignant melanoma(see also leukemia, lymphoma, other)
melanoma DNA vaccineSan Diego, CA
Memorial Sloan-Kettering Cancer CenterNew York, NY
malignant melanoma
EisaiWoodcliff Lake, NJ
malignant melanoma
Medicines in Development for Cancer
Medicines in Development Cancer 2012 89
SKIN CANCER
Product Name Sponsor Indication Development Status
(Orphan Drug)
Progen PharmaceuticalsQueensland, Australia
malignant melanoma(see also liver) www.progen.com.au
MVax®
melanoma vaccineAVAX TechnologiesPhiladelphia, PA
malignant melanoma
NX-101 NexGenixNew York, NY
Ontak®
denileukin diftitoxEisaiWoodcliff Lake, NJ
malignant melanoma
PEG arginine deiminase Polaris PharmaceuticalsSan Diego, CA
metastatic malignant melanoma (see also liver, prostate, other)
Picato®
ingenol mebutateLEO PharmaParsippany, NJ
basal cell cancer
POL-103A(melanoma vaccine)(Orphan Drug)
PolynomaSan Diego, CA
malignant melanoma
immunotherapeutic (recombinant)
GlaxoSmithKline metastatic malignant melanoma(see also lung)
Pain Therapeutics malignant melanoma
PV-10(rose bengal sodium)(Orphan Drug)
Provectus Pharmaceuticals malignant melanoma(see also liver)
(raf kinase inhibitor)Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also solid tumors) (888) 669-6682
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
malignant melanoma(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, sarcoma, solid tumors)
(BRAF kinase inhibitor)RocheNutley, NJ
malignant melanoma
RG7636(antibody drug conjugate)
RocheNutley, NJ
malignant melanoma
Medicines in Development for Cancer
Medicines in Development Cancer 201290
SKIN CANCER
Product Name Sponsor Indication Development Status
talminogene laherparepvec Amgen malignant melanoma
Tasigna®
nilotinibNovartis PharmaceuticalsEast Hanover, NJ
malignant melanoma (c-Kit mutation)(see also leukemia, stomach) (888) 669-6682
tesetaxel(Orphan Drug)
GentaBerkeley Heights, NJ
malignant melanoma(see also bladder, breast, prostate, stomach)
(908) 286-9800
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
malignant melanoma(see also breast, kidney, multiple myeloma, prostate, other)
(888) 669-6682
TNFerade™golnerminogene pradenovec
GenVecGaithersburg, MD
malignant melanoma(see also head/neck, prostate, stomach)
trametinib GlaxoSmithKline malignant melanoma (monotherapy)(see also leukemia, lung, lymphoma, multiple myeloma, pancreatic)--------------------------------------------------malignant melanoma (combination therapy)
-------------------------------------------
veglin (VEGF antisense)
VasGene TherapeuticsLos Angeles, CA
Kaposi’s sarcoma(see also lung, kidney) (323) 221-7818
YERVOY®
ipilimumabBristol-Myers SquibbPrinceton, NJ
melanoma (adjuvant therapy),melanoma brain metastases(see also lung, prostate)
in clinical trials
Zadaxin®
thymalfasin alfa 1(Orphan Drug)
SciClone PharmaceuticalsFoster City, CA
malignant melanoma(see also liver)
SOLID TUMORS
Product Name Sponsor Indication Development Status
AbGn-7 AbGenomicsLos Altos, CA
(sirolimus albumin bound)CelgeneSummit, NJ (908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 91
SOLID TUMORS
Product Name Sponsor Indication Development Status
(aurora kinase inhibitor)Abbott LaboratoriesAbbott Park, IL
late-stage solid tumors(see also other)
ABT-700(c-Met inhibitor)
Abbott LaboratoriesAbbott Park, IL
ABT-767(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
ABT-806(EGFR inhibitor)
Abbott LaboratoriesAbbott Park, IL
AC220(quizartinib)
Ambit BiosciencesSan Diego, CA
Astellas Pharma US
(see also leukemia)
AEZS-112 AEterna Zentaris Basking Ridge, NJ
(see also lymphoma)
AcusphereLexington, MA
(tubulin inhibitor) Albany, NY
Bessor PharmaFramingham, MA
www.amriglobal.com
AlloStim™Shoham, Israel
(see also other)www.immunovative.co.il
Alocrest™vinorelbine liposomal
Talon TherapeuticsSan Mateo, CA
(see also lymphoma)
AMG 208(c-Met inhibitor)
Amgen
AMG 337(c-Met inhibitor)
Amgen
AMG 780(angioprotein inhibitor)
Amgen
AMG 820(c-fms antagonist)
Amgen
Medicines in Development for Cancer
Medicines in Development Cancer 201292
SOLID TUMORS
Product Name Sponsor Indication Development Status
AMG 900(aurora kinase inhibitor)
Amgen (see also other)
AmplimmuneGaithersburg, MD (301) 309-9800
anti-CD137 Bristol-Myers SquibbPrinceton, NJ
GenentechSouth San Francisco, CA
anti-PD-L1 Bristol-Myers SquibbPrinceton, NJ
Aplidin®
plitidepsinPharmaMarMadrid, Spain
(see also lymphoma, multiple myeloma) www.pharmamar.com
AR-12 Arno TherapeuticsFlemington, NJ
(see also lymphoma)(862) 703-7170
AR-67 Arno TherapeuticsFlemington, NJ
(see also brain, leukemia)(862) 703-7170
ARQ 092(AKT inhibitor)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
inoperable/unresectable late-stage solid tumors
ARQ 621 ArQuleWoburn, MA
late-stage solid tumors(see also other)
ARQ 736(BRAF inhibitor)
ArQuleWoburn, MA
late-stage solid tumors
ARQ 761(E2F1 stimulant)
ArQuleWoburn, MA
ARRY-162(MEK inhibitor)
Array BioPharmaBoulder, CO
late-stage solid tumors(see also skin)
(KSP inhibitor)Array BioPharmaBoulder, CO
(see also leukemia, multiple myeloma)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 93
SOLID TUMORS
Product Name Sponsor Indication Development Status
ASG-22ME AgensysSanta Monica, CA
Seattle GeneticsBothell, WA
ASP3026 Astellas Pharma US late-stage solid tumors(see also lymphoma)
(CDK inhibitor)Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, multiple myeloma)
AT9283(aurora/Jak2 inhibitor)
Astex PharmaceuticalsDublin, CA
(see also leukemia, lymphoma, multiple myeloma)
AT13387(Hsp90 inhibitor)
Astex PharmaceuticalsDublin, CA
refractory solid tumors(see also stomach)
(docetaxel liposomal)Azaya Therapeutics
(JAK1/JAK2 inhibitor)AstraZenecaWilmington, DE (800) 236-9933
(TOR kinase inhibitor)AstraZenecaWilmington, DE (800) 236-9933
(FGFR tyrosine kinase inhibitor)AstraZenecaWilmington, DE (800) 236-9933
(AKT inhibitor)Astex PharmaceuticalsDublin, CA
AstraZenecaWilmington, DE
(800) 236-9933
AZD8330
(MEK inhibitor)
Array BioPharmaBoulder, CO
AstraZenecaWilmington, DE
(800) 236-9933
AZD8931(erbB kinase inhibitor)
AstraZenecaWilmington, DE
(see also breast)(800) 236-9933
(Pan-CDK inhibitor)Bayer HealthCare PharmaceuticalsWayne, NJ
late-stage solid tumors
(antibody-drug conjugate)Bayer HealthCare PharmaceuticalsWayne, NJ
Medicines in Development for Cancer
Medicines in Development Cancer 201294
SOLID TUMORS
Product Name Sponsor Indication Development Status
Bayer HealthCare PharmaceuticalsWayne, NJ
ἀ pathway inhibitor)Bayer HealthCare PharmaceuticalsWayne, NJ
(antibody drug conjugate)Bayer HealthCare PharmaceuticalsWayne, NJ
(stemness kinase inhibitor)Boston BiomedicalNorwood, MA
late-stage solid tumors(781) 278-0900
(stemness inhibitor)Boston BiomedicalNorwood, MA
late-stage solid tumors(781) 278-0900
belotecan OnKor PharmaceuticalsSeattle, WA
(kinase inhibitor)Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
BGJ398(FGF-R kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
BGT226 Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
BHQ880(mAb)
Novartis PharmaceuticalsEast Hanover, NJ
(see also multiple myeloma)(888) 669-6682
(aurora kinase B inhibitor) Pharmaceuticals(see also leukemia)
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Medicines in Development for Cancer
Medicines in Development Cancer 2012 95
SOLID TUMORS
Product Name Sponsor Indication Development Status
(TYK2 inhibitor) Pharmaceuticals
Cambridge, MA (617) 679-2000
Cambridge, MA (617) 679-2000
(docetaxel nanopharmaceutical) Cambridge, MA
BMN-673(PARP inhibitor)
BioMarin PharmaceuticalsNovato, CA
(see also other)
Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
BYL719 Novartis PharmaceuticalsEast Hanover, NJ
late-stage solid tumors(888) 669-6682
CA-18C3 XBiotech (see also cancer-related, other)
CALAA 01(siRNA)
Calando PharmaceuticalsPasadena, CA (626) 683-7200
Onyx PharmaceuticalsSouth San Francisco, CA
(see also multiple myeloma)
(peptide mimetic)CanBasShizouka, Japan
(see also lung)www.canbas.co.jp
(kinase inhibitor)CelgeneSummit, NJ
(see also lymphoma, multiple myeloma) (908) 673-9000
CC-122 CelgeneSummit, NJ
(see also lymphoma, multiple myeloma) (908) 673-9000
CDX-1127 Celldex TherapeuticsNeedham, MA
(see also other)
(cancer vaccine)Celldex TherapeuticsNeedham, MA
solid tumors expressing theNY-ESO-1 protein
CEP-11981 CephalonFrazer, PA
Medicines in Development for Cancer
Medicines in Development Cancer 201296
SOLID TUMORS
Product Name Sponsor Indication Development Status
CG201(cancer vaccine)
CG TherapeuticsSeattle, WA
CRLX101 Cerulean PharmaCambridge, MA
late-stage solid tumors
crolibulin EpiCept
CUDC-101 CurisLexington, MA
CVX 060
(Ang2 antagonist)New York, NY
(see also kidney)
(CK2 inhibitor)Cylene PharmaceuticalsSan Diego, CA
(see also multiple myeloma)
CYC116(aurora kinase/VEGFR2 inhibitor)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
CYT-6091(Aurimune) Rockville, MD
D-1MT NewLink GeneticsAmes, IA
(see also breast)
D-3263(TRPM8 protein stimulant)
DendreonSeattle, WA
dacomitinibNew York, NY
(see also lung)
darinaparsinNew York, NY
(see also liver, lymphoma, multiple myeloma)
Daiichi SankyoParsippany, NJ
Daiichi SankyoParsippany, NJ
Medicines in Development for Cancer
Medicines in Development Cancer 2012 97
SOLID TUMORS
Product Name Sponsor Indication Development Status
EisaiWoodcliff Lake, NJ
metastatic solid tumors(see also brain, head/neck, liver, skin, stomach)
EC17 EndocyteWest Lafayette, IN www.endocyte.com
EndocyteWest Lafayette, IN www.endocyte.com
elsamitrucin Spectrum PharmaceuticalsHenderson, NV
late-stage solid tumors
(c-Met kinase inhibitor)EMD SeronoRockland, MA (800) 283-8088
enavatuzumab Abbott LaboratoriesAbbott Park, IL
EP-100 Esperance PharmaceuticalsBaton Rouge, LA
ETBX-011cancer vaccine
EtubicsSeattle, WA
late-stage metastatic solid tumors
etirinotecan pegol (NKTR-102)
Nektar TherapeuticsSan Francisco, CA
combination therapy(see also breast, colorectal, ovarian)
EZN-2208 Enzon PharmaceuticalsPiscataway, NJ
solid tumors (pediatric)(see also breast, colorectal)--------------------------------------------------combination therapy
-------------------------------------------
EZN-2968 Enzon PharmaceuticalsPiscataway, NJ
(see also lymphoma)
(AV-299)AVEO PharmaceuticalsCambridge, MA
(see also lung)
GE HealthcareWaukesha, WI
Bethesda, MD
solid tumors (diagnosis)
FP-1039/HGS1036 Five Prime TherapeuticsSouth San Francisco, CA
Human Genome SciencesRockville, MD
late-stage solid tumors
Medicines in Development for Cancer
Medicines in Development Cancer 201298
SOLID TUMORS
Product Name Sponsor Indication Development Status
G-202 GenSpera
GC1008(fresolimumab)
GenzymeCambridge, MA
GDC-0032 GenentechSouth San Francisco, CA
metastatic solid tumors
GDC-0068(Akt inhibitor)
GenentechSouth San Francisco, CA
(small molecule)GenentechSouth San Francisco, CA
(see also lymphoma)
(ChK1 inhibitor)GenentechSouth San Francisco, CA
(see also lymphoma)
GenentechSouth San Francisco, CA
(see also lymphoma)
GDC-0623(MEK inhibitor)
GenentechSouth San Francisco, CA
metastatic solid tumors
GDC-0917 GenentechSouth San Francisco, CA
(see also lymphoma)
GDC-0973(MEK inhibitor)
GenentechSouth San Francisco, CA
(see also skin cancer)
GDC-0980
inhibitor)
GenentechSouth San Francisco, CA
(see also breast, lymphoma)
(toposisomerase-1 inhibitor)GenzymeCambridge, MA
KiraxBonita Springs, FL
(brachyury peptide vaccine) Louisville, CO
GL-ONC1 GeneluxSan Diego, CA
GO-203-2c Genus OncologyVernon Hills, IL
late-stage solid tumors
Medicines in Development for Cancer
Medicines in Development Cancer 2012 99
SOLID TUMORS
Product Name Sponsor Indication Development Status
(polio-like kinase inhibitor)GlaxoSmithKline (see also lymphoma)
GSK690693(AKT kinase inhibitor)
GlaxoSmithKline (see also lymphoma)
GSK1070916A(selective aurora kinase B/C inhibitor)
GlaxoSmithKline
GlaxoSmithKline (see also lymphoma)
(protein kinase B inhibitor)GlaxoSmithKline (see also lymphoma)
(FAK inhibitor)GlaxoSmithKline
GSK2636771 GlaxoSmithKline
HSP990(heat shock protein)
Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
Bristol-Myers SquibbPrinceton, NJ
(cancer vaccine)NY-ESO-1 antigen-expressing solid tumors www.immunofrontier.com
Waltham, MA
(c-Met inhibitor)Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
Wilmington, DE
(see also skin)
indium-111 (ABT-806) Abbott LaboratoriesAbbott Park, IL
solid tumors (diagnosis)
(mTOR inhibitor) La Jolla, CA
(see also lymphoma, multiple myeloma)
La Jolla, CA
Medicines in Development for Cancer
Medicines in Development Cancer 2012100
SOLID TUMORS
Product Name Sponsor Indication Development Status
CytRxLos Angeles, CA
(see also pancreatic, sarcoma)
CytRxLos Angeles, CA
(see also leukemia)
(angiogenesis inhibitor)Jubilant BiosysMalvern, PA
(Hdm2 inhibitor)Johnson & Johnson Pharmaceutical Research & DevelopmentRaritan, NJ
late-stage solid tumors(see also lung, prostate)
JX-929 Jennerex BiotherapeuticsSan Francisco, CA
Karenitecin® BioNumerik Pharmaceuticals solid tumors (adults and pediatric)(see also lung, ovarian)
KHK-2866 Kyowa Hakko Kirin PharmaPrinceton, NJ
advanced solid tumors(see also ovarian) (609) 919-1100
(panobinostat)Novartis PharmaceuticalsEast Hanover, NJ
(see also kidney, leukemia, multiple myeloma, prostate) (888) 669-6682
(aldosterone synthase inhibitor)Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
LCL161 Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
(erismodegib)Novartis PharmaceuticalsEast Hanover, NJ
solid tumors (adults and pediatric)(see also leukemia, pancreatic, skin) (888) 669-6682
LDK378(ALK inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
LEE011 Novartis PharmaceuticalsEast Hanover, NJ
(see also lymphoma)(888) 669-6682
(Smo antagonist)Novartis PharmaceuticalsEast Hanover, NJ (888) 669-6682
L-MDAM BioNumerik Pharmaceuticals
(MTF-1 inhibitor)Lorus Therapeutics metastatic solid tumors
Medicines in Development for Cancer
Medicines in Development Cancer 2012 101
SOLID TUMORS
Product Name Sponsor Indication Development Status
LP-261 Locus PharmaceuticalsBlue Bell, PA
lurbinectedin PharmaMarMadrid, Spain
(see also leukemia)www.pharmamar.com
(NADH oxidase inhibitor)Marshall EdwardsSan Diego, CA
refractory solid tumors
(anti-CEA BiTE)AstraZenecaWilmington, DE
Gaithersburg, MD
(800) 236-9933(301) 398-0000
AstraZenecaWilmington, DE
Gaithersburg, MD
(800) 236-9933(301) 398-0000
AstraZenecaWilmington, DE
Gaithersburg, MD
(800) 236-9933(301) 398-0000
(anti-ANG-2 mAb)AstraZenecaWilmington, DE
Gaithersburg, MD
(800) 236-9933(301) 398-0000
MG-1102 Green CrossYongin, South Korea
Mogam Biotechnology Research
Yongin, South Korea
second-line solid tumorswww.eng.greencross.com
MGA271 (anti-B7-H3)
MacroGenicsRockville, MD
refractory metastatic solid tumors
MGAH22 (anti-HER2 mAb) MacroGenicsRockville, MD
GenentechSouth San Francisco, CA
MerckWhitehouse Station, NJ (800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012102
SOLID TUMORS
Product Name Sponsor Indication Development Status
MerckWhitehouse Station, NJ
metastatic late-stage solid tumors(800) 672-6372
(PARP inhibitor)MerckWhitehouse Station, NJ (800) 672-6372
(aurora kinase A inhibitor)MerckWhitehouse Station, NJ
Vertex PharmaceuticalsCambridge, MA
(800) 672-6372
MerckWhitehouse Station, NJ
(see also leukemia)(800) 672-6372
MLN0128 Millennium PharmaceuticalsCambridge, MA
(see also other)
(tandutinib)Millennium PharmaceuticalsCambridge, MA
MLN1117 Millennium PharmaceuticalsCambridge, MA
(raf kinase inhibitor)Millennium PharmaceuticalsCambridge, MA
(NEDD8 inhibitor)Millennium PharmaceuticalsCambridge, MA
(see also other)
MLN8237(alisertib)
Millennium PharmaceuticalsCambridge, MA
(see also lymphoma)
MLN9708 (ixazomib)
Millennium PharmaceuticalsCambridge, MA
(see also lymphoma, multiple myeloma)
(EGFR antagonist)Merrimack PharmaceuticalsCambridge, MA
mocetinostat(MGCD0103, HDAC inhibitor)
MethylGeneMontreal, Canada
(see also leukemia, lymphoma)
MPDL-3280A GenentechSouth San Francisco, CA
Medicines in Development for Cancer
Medicines in Development Cancer 2012 103
SOLID TUMORS
Product Name Sponsor Indication Development Status
(MEK inhibitor)EMD SeronoRockland, MA (800) 283-8088
MTKi-328 BeiGeneBeijing, China www.beigene.com
MTRN-2696 Spectrum PharmaceuticalsHenderson, NV
NKP-1339 Niiki PharmaHoboken, NJ
(pegylated docetaxel)Nektar TherapeuticsSan Francisco, CA
(CDC7 protein kinase inhibitor)Nerviano Medical ServicesNerviano, Italy www.nervianoms.com
NMS-1286937 Nerviano Medical ServicesNerviano, Italy www.nervianoms.com
(marizomib)Nereus PharmaceuticalsSan Diego, CA
(see also lymphoma, multiple myeloma)
olaparib(PARP inhibitor)
AstraZenecaWilmington, DE (800) 236-9933
Omapro™omacetaxine
CephalonFrazer, PA
(see also leukemia)
Bayer HealthCare PharmaceuticalsWayne, NJ
OncoMed PharmaceuticalsRedwood City, CA
OMP-21M18 GlaxoSmithKline
OncoMed PharmaceuticalsRedwood City, CA
(notch pathway)GlaxoSmithKline
OncoMed PharmaceuticalsRedwood City, CA
omtriptolide PharmagenesisRedwood City, CA
Pierre Fabre PharmaceuticalsParsippany, NJ
www.pierre-fabre.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012104
SOLID TUMORS
Product Name Sponsor Indication Development Status
ONT-10(cancer vaccine)
OncothyreonSeattle, WA (206) 769-9219
ONX-0801 Onyx PharmaceuticalsSouth San Francisco, CA
Otsuka America PharmaceuticalRockville, MD
oprozomib Onyx PharmaceuticalsSouth San Francisco, CA
oral azacitidine CelgeneSummit, NJ
(see also leukemia, lung, lymphoma)(908) 673-9000
ortataxel Spectrum PharmaceuticalsHenderson, NV
taxane-refractory solid tumors
(c-kit/VEGFR-2) Farmingdale, NY (631) 962-0600
p28 peptide CDG TherapeuticsChicago, IL www.cdgti.com
paclitaxel liposomal Sun PharmaMumbai, India www.sunpharma.com
palifosfamideNew York, NY
(see also lung, sarcoma)
pbi-shRNA™ STMN1 LP
(anti-stathim gene therapy)Gradalis
perifosine AEterna ZentarisBasking Ridge, NJ
solid tumors (pediatric)(see also brain, colorectal, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, stomach)
PF-00337210(VEGFR2 antagonist) New York, NY
(ALK-1 mAb) New York, NY
Medicines in Development for Cancer
Medicines in Development Cancer 2012 105
SOLID TUMORS
Product Name Sponsor Indication Development Status
New York, NY
New York, NY
(see also other)
New York, NY
(see also other)
Progen PharmaceuticalsQueensland, Australia
(see also lymphoma)www.progen-pharma.com
PLX3397(CSF-1R kinase inhibitor)
PlexxikonBerkeley, CA
metastatic solid tumors(see also brain, leukemia, lymphoma)
PharmaMarMadrid, Spain www.pharmamar.com
(bcl-2 oncogene inhibitor)ProNAi TherapeuticsAnn Arbor, MI
(CBP/catenin inhibitor) Yokohama, Japan www.prismbiolab.com
PRLX93936 Prolexys Pharmaceuticals
PTC299 PTC Therapeutics (see also breast, other)(908) 222-7000
purine nucleoside phosphorylasegene therapy
PNP TherapeuticsBirmingham, AL www.pnptherapeutics.com
Pathway TherapeuticsSan Francisco, CA www.pathwaytx.com
Quintessence BiosciencesMadison, WI
(raf kinase inhibitor)Novartis PharmaceuticalsEast Hanover, NJ
(see also skin)(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012106
SOLID TUMORS
Product Name Sponsor Indication Development Status
regorafenib Bayer HealthCare PharmaceuticalsWayne, NJ
(see also colorectal, kidney, lung, stomach)
Reolysin®
reovirusOncolytics BiotechCalgary, Canada
solid tumors (pediatric)(see also brain, colorectal, head/neck, lung, ovarian, pancreatic, sarcoma, skin)
RG7112(MDM2 antagonist)
RocheNutley, NJ
(see also other)
RG7116(ErbB-3 receptor antagonist)
Roche Nutley, NJ
(anti-CSF-1R mAb)RocheNutley, NJ
RG7167 RocheNutley, NJ
(MAP/raf inhibitor)RocheNutley, NJ
RG7321 GenentechSouth San Francisco, CA
RocheNutley, NJ
(NRP1 antagonist)GenentechSouth San Francisco, CA
RocheNutley, NJ
RocheNutley, NJ
RG7388(MDM2 inhibitor)
RocheNutley, NJ
(see also other)
(HFGR-1877S)GenentechSouth San Francisco, CA
(see also multiple myeloma)
(mAb)GenentechSouth San Francisco, CA
(mAb)GenentechSouth San Francisco, CA
advanced solid tumors
Medicines in Development for Cancer
Medicines in Development Cancer 2012 107
SOLID TUMORS
Product Name Sponsor Indication Development Status
RG7602 GenentechSouth San Francisco, CA
(see also lymphoma)
robatumumab MerckWhitehouse Station, NJ
solid tumors (combination therapy)(see also colorectal, sarcoma)--------------------------------------------------solid tumors (pediatric)
(800) 672-6372-------------------------------------------
(800) 672-6372
RRx-001 RadioRxMountain View, CA
sapacitabine (CYC682)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
(see also leukemia, lung)
(Met kinase inhibitor) Bridgewater, NJ
Bridgewater, NJ
combination therapyMerck SeronoGeneva, Switzerland
Bridgewater, NJ
combination therapy
inhibitor)
Merck SeronoGeneva, Switzerland
Bridgewater, NJ
(MM-121) companion diagnostic
Merrimack PharmaceuticalsCambridge, MA
Bridgewater, NJ
solid tumors (diagnosis)
(REGN910)(anti-Ang2 mAb)
Regeneron Pharmaceuticals
Bridgewater, NJ
(maytansin-loaded anti-DS6) Bridgewater, NJ
DS6-positive solid tumors
SB989 (pracinostat) Oakland, CA
late-stage solid tumors(see also leukemia, other)
Medicines in Development for Cancer
Medicines in Development Cancer 2012108
SOLID TUMORS
Product Name Sponsor Indication Development Status
MerckWhitehouse Station, NJ (800) 672-6372
seliciclib (CYC202)
Cyclacel PharmaceuticalsBerkeley Heights, NJ
(see also head/neck)
selumetinib
(MEK inhibitor)
AstraZenecaWilmington, DE (800) 236-9933
selumetinib
MK2206 combination (MEK/AKT inhibitor)
AstraZenecaWilmington, DE
MerckWhitehouse Station, NJ
(800) 236-9933(800) 672-6372
SF1126 Semafore PharmaceuticalsIndianapolis, IN
(see also leukemia, multiple myeloma)
Taxolog
solid tumor immunotherapy(mAb)
GenentechSouth San Francisco, CA
sonepcizumab LpathSan Diego, CA
(endothelin B receptor agonist)Spectrum PharmaceuticalsHenderson, NV
TAG vaccine Gradalis
(gonadotrophin hormone-releasing hormone receptor antagonist)
Millennium PharmaceuticalsCambridge, MA
(hedgehog signaling pathway inhibitor)
Millennium PharmaceuticalsCambridge, MA
TAK-701(HGF inhibitor)
Millennium PharmaceuticalsCambridge, MA
TAK-733(MEK inhibitor)
Millennium PharmaceuticalsCambridge, MA
Medicines in Development for Cancer
Medicines in Development Cancer 2012 109
SOLID TUMORS
Product Name Sponsor Indication Development Status
TAK-960(Plk1 inhibitor)
Millennium PharmaceuticalsCambridge, MA
teglarinad CephalonFrazer, PA
(see also lymphoma)
terameprocol Erimos Pharmaceuticals(see also brain, cervical, head/neck, other)
TKM-PLK1(RNAi)
Tekmira PharmaceuticalsBurnaby, Canada
(see also lymphoma)
TL-32711(birinapant)
TetraLogic PharmaceuticalsMalvern, PA
(see also leukemia)(610) 889-9900
TLC-388 TLC BiopharmaceuticalsSouth San Francisco, CA
TRC093 TRACON PharmaceuticalsSan Diego, CA
TRC102(DNA repair inhibitor)
TRACON PharmaceuticalsSan Diego, CA
tremelimumab AstraZenecaWilmington, DE
Gaithersburg, MD
(800) 236-9933(301) 398-0000
TST-10088 CangeneWinnipeg, Canada
(anti-HB-EGF antibody)Amgen
Daiichi Sankyo USParsippany, NJ
Drais PharmaceuticalsBridgewater, NJ
(see also lymphoma)
MerckWhitehouse Station, NJ (800) 672-6372
(telomerase inhibitor vaccine)GeronMenlo Park, CA
MerckWhitehouse Station, NJ
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012110
SOLID TUMORS
Product Name Sponsor Indication Development Status
VGX-100(VEGF-C mAb)
Circadian TechnologiesVictoria, Australia www.circadian.com.au
VTX-2337 VentiRx PharmaceuticalsSeattle, WA
(see also lymphoma)
VaccinexRochester, NY
Munich, Germany www.wilex.de
X-82(dual VEGFR/PDGFR inhibitor)
TyrogenexWest Palm Beach, FL
advanced solid tumors
Xalkori®
crizotinib New York, NY
(see also lung)
XMT-1001 Mersana TherapeuticsCambridge, MA
XMT-1107 Mersana TherapeuticsCambridge, MA
STOMACH CANCER
Product Name Sponsor Indication Development Status
AT-101(oral pan Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
late-stage esophageal cancer (combination therapy)(see also brain, leukemia, lung, lymphoma, prostate)
AT13387(Hsp90 inhibitor)
Astex PharmaceuticalsDublin, CA
late-stage gastrointestinal stromal
(see also solid tumors)
AUY922(Hsp90 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ (see also breast, colorectal, lung,
multiple myeloma)(888) 669-6682
Cambridge, MA (see also breast) (617) 679-2000
Medicines in Development for Cancer
Medicines in Development Cancer 2012 111
STOMACH CANCER
Product Name Sponsor Indication Development Status
crenolanib AROG Pharmaceuticals(see also brain)
EisaiWoodcliff Lake, NJ
gastric cancer (combination therapy)(see also brain, head/neck, liver, skin, solid tumors)
ERBITUX® cetuximab
Bristol-Myers SquibbPrinceton, NJ
Eli LillyIndianapolis, IN
gastric cancer(see also colorectal)
in clinical trials
ganetespib (Hsp90i)
Synta PharmaceuticalsLexington, MA
esophageal cancer, gastric cancer,
(see also breast, colorectal, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin)
masitinib(Orphan Drug)
AB Science USAShort Hills, NJ (see also pancreatic)
Opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
esophageal cancer(see also brain, lung, ovarian, other)
perifosine AEterna ZentarisBasking Ridge, NJ (see also brain, colorectal, kidney,
leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors)
polyclonal antibody stimulator(Orphan Drug)
Cancer AdvancesDurham, NC
gastric cancer(see also colorectal, pancreatic) (919) 361-2162
ramucirumab Eli LillyIndianapolis, IN
Bridgewater, NJ
gastric cancer(see also breast, colorectal)
regorafenib(Orphan Drug)
Bayer HealthCare PharmaceuticalsWayne, NJ (see also colorectal, kidney, lung,
solid tumors)
S-1 Taiho Pharma U.S.A.Princeton, NJ
gastric cancer
Tasigna®nilotinib(Orphan Drug)
Novartis PharmaceuticalsEast Hanover, NJ (see also leukemia, skin) (888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012112
STOMACH CANCER
Product Name Sponsor Indication Development Status
telatinib(Orphan Drug)
ACT BiotechSan Francisco, CA
gastric cancer (combination therapy)(see also colorectal)
tesetaxel(Orphan Drug)
GentaBerkeley Heights, NJ
gastric cancer(see also bladder, breast, prostate, skin)
(908) 286-9800
TNFerade™golnerminogene pradenovac
GenVecGaithersburg, MD
esophageal cancer(see also head/neck, prostate, skin)
trebananib (AMG386)
Amgen esophageal cancer, gastric cancer(see also breast, colorectal, kidney, liver, ovarian, other)
Tykerb®
lapatinibGlaxoSmithKline gastric cancer
(see also breast, head/neck)
uridine triacetate Gaithersburg, MD
gastric cancer(see also pancreatic)
Xeloda®
capecitabineGenentechSouth San Francisco, CA
esophageal cancer (see also brain, colorectal, liver)
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
AG103 ActoGenixZwijnaarde, Belgium
oral mucositis associated with cancertreatment www.actogenix.com
AP1903 Bellicum Pharmaceuticals graft-versus-host disease(see also prostate)
ARX-02 (sufentanil sublingual)
AcelRx PharmaceuticalsRedwood City, CA
breakthrough cancer pain
CA-18C3 XBiotech cancer-related cachexia(see also other, solid tumors)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 113
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
(oltipraz)Canopus BioPharmaStudio City, CA
chemotherapy- and radiation-inducedmucositis www.canopusbiopharma.com
CLT-008 Cellerant TherapeuticsSan Carlos, CA
chemotherapy-related neutropenia(see also other)
dronabinol oral solutionPhoenix, AZ
chemotherapy-induced nausea and vomiting (602) 910-2617
EisaiWoodcliff Lake, NJ
oral mucositis
Emend®
aprepitantMerckWhitehouse Station, NJ
chemotherapy-induced nausea and vomiting (pediatric) (800) 672-6372
Emend® IV
aprepitantMerckWhitehouse Station, NJ
chemotherapy-induced nausea and vomiting (pediatric) (800) 672-6372
fentanyl inhalation Akela Pharma cancer pain
ferroportin mAb Eli LillyIndianapolis, IN
anemia associated with cancer
fulranumab Johnson & Johnson PharmaceuticalResearch & DevelopmentRaritan, NJ
cancer pain (adjunctive treatment)
hepcidin mAb Eli LillyIndianapolis, IN
anemia associated with cancer
LG631 LentigenGaithersburg, MD
chemoprotection in patients undergoing treatment for glioblastoma
mesenchymal stem cell therapy(Orphan Drug)
MesoblastNew York, NY
for bone marrow regeneration in patients undergoing bone marrow transplantation
(212) 880-2060
morphine intranasal Marina BiotechBothell, WA
cancer pain
MultiStem®
stem cell therapy(Orphan Drug)
Athersys Cleveland, OH
graft-versus-host disease in patients undergoing bone marrow transplant
Medicines in Development for Cancer
Medicines in Development Cancer 2012114
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
nabiximols Otsuka America PharmaceuticalRockville, MD
cancer pain (adjunctive treatment)
netupitant/palonosetron Helsinn TherapeuticsBridgewater, NJ
chemotherapy-induced nausea and vomiting
NP-2 gene therapy(intradermal)
Diamyd MedicalPittsburgh, PA
cancer pain
Nplate®
romiplostimAmgen chemotherapy-associated
thrombocytopenia
PHY906 PhytoCeutica chemotherapy-induced gastrointestinal disorders(see also colorectal, liver, pancreatic)
Prochymal®
remestemcel-L(Orphan Drug)
Osiris TherapeuticsColumbia, MD
graft-versus-host disease
ProDermaCel™norepinephrine topical
ProCertus BioPharmMadison, WI
prevention of oral mucositis, prevention of radiation-induced skin damage
(608) 273-8862
Promacta®
eltrombopagGlaxoSmithKline chemotherapy-induced
thrombocytopenia (888) 669-6682
REGiMMUNESanta Clara, CA
graft-versus-host diseasewww.regimmune.com
rolapitant TESAROWaltham, MA
chemotherapy-induced nausea and vomiting (339) 970-0900
SGX201 SoligenixPrinceton, NJ
acute radiation enteritis in patients with cancer
sotatercept (ACE-011)
CelgeneSummit, NJ
chemotherapy-induced anemia(see also other) (908) 673-9000
tanezumabNew York, NY
cancer pain (adjunctive treatment)
Tavocept®
dimesnaBioNumerik Pharmaceuticals chemoprotection
(see also lung)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 115
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
T-cell replacement therapy Bellicum Pharmaceuticals graft-versus-host disease in patients with late-stage cancer undergoing bone marrow transplantation
(Orphan Drug)
Kiadis PharmaAmsterdam, Netherlands
graft-versus-host diseasewww.kiadis.com
TXA127 Tarix PharmaceuticalsCambridge, MA
chemotherapy-induced thrombocytopenia www.tarixpharma.com
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
steroid-refractory graft-versus-host disease (see also leukemia, lymphoma, other)
XenomeQueensland, Australia
cancer painwww.xenome.com
Xgeva™denosumab
Amgen prevention of cancer-related bone damage or malignant hypercalcemia(see also multiple myeloma, other)
OTHER CANCERS
Product Name Sponsor Indication Development Status
United TherapeuticsSilver Spring, MD
peritoneal cancer(see also brain, sarcoma) (301) 608-9292
Å6 Angstrom PharmaceuticalsSolana Beach, CA
gynecologic cancer(see also ovarian)
(aurora kinase inhibitor)Abbott LaboratoriesAbbott Park, IL
hematological malignancies(see also solid tumors)
ABT-888 (veliparib)(PARP inhibitor)
Abbott LaboratoriesAbbott Park, IL
fallopian tube cancer(see also brain, breast, colorectal, lung, lymphoma, ovarian, prostate, skin)
AEZS-108 AEterna ZentarisBasking Ridge, NJ
late-stage endometrial cancer(see also bladder, ovarian, prostate)
AlloStim™Shoham, Israel
hematological malignancies(see also solid tumors) www.immunovative.co.il
Medicines in Development for Cancer
Medicines in Development Cancer 2012116
OTHER CANCERS
Product Name Sponsor Indication Development Status
Alpharadin®
radium-223 chlorideBayer HealthCare PharmaceuticalsWayne, NJ
bone metastases from castration-resistant prostate cancer(see also solid tumors)
application submitted
ALT-801 Altor BioScienceMiramar, FL
urogenital cancer(see also skin)
AMG 319 Amgen hematological malignancies
AMG 900(aurora kinase inhibitor)
Amgen hematological malignancies(see also solid tumors)
anti-CD70 ADC Bristol-Myers SquibbPrinceton, NJ
hematological malignancies
Bristol-Myers SquibbPrinceton, NJ
hematological malignancies
ARQ 621 ArQuleWoburn, MA
hematological malignancies(see also solid tumors)
Avastin®
bevacizumabGenentechSouth San Francisco, CA
high-risk carcinoid tumor(see also brain, breast, colorectal, lung, ovarian)
BAY 10-02670 Bayer HealthCare PharmaceuticalsWayne, NJ
uterine leiomyoma
belinostat Spectrum PharmaceuticalsHenderson, NV
peritoneal cancer, thymoma(see also colorectal, leukemia, liver, lung, lymphoma, ovarian)--------------------------------------------------
--------------------------------------------------recurrent hematological malignancies(combination therapy)
-------------------------------------------
-------------------------------------------
BKM120 Novartis PharmaceuticalsEast Hanover, NJ
second-line endometrial cancer, second-line urogenital cancer(see also brain, breast, lung)
(888) 669-6682
BMN-673(PARP inhibitor)
BioMarin PharmaceuticalsNovato, CA
hematological malignancies
Medicines in Development for Cancer
Medicines in Development Cancer 2012 117
OTHER CANCERS
Product Name Sponsor Indication Development Status
BP-100-1-01 Bio-PathOgden, Utah
hematological malignancies
CA-18C3 XBiotech hematological malignancies(see also cancer-related, solid tumors)
cabozantinib
(Orphan Drug)
ExelixisSouth San Francisco, CA
medullary thyroid cancer(see also breast, kidney, lung, ovarian, prostate)
catumaxomab Fresenius Biotech North AmericaWaltham, MA
malignant ascites(see also ovarian) www.fresenius-biotech.com
CDX-1127 Celldex TherapeuticsNeedham, MA
hematological malignancies(see also solid tumors)
clodronic acid Bayer HealthCare PharmaceuticalsWayne, NJ
bone metastases
CLT-008 Cellerant TherapeuticsSan Carlos, CA
hematological malignancies(see also cancer-related)
(Orphan Drug)
Cornerstone PharmaceuticalsCranbury, NJ
hematological malignancies(see also pancreatic)
dalotuzumab MerckWhitehouse Station, NJ
neuroendocrine tumors(see also breast, lung, pancreatic) (800) 672-6372
GenentechSouth San Francisco, CA second-line peritoneal cancer
(see also ovarian)
(lapuleucel-T) dendritic cell vaccine
Dendreon Seattle, WA
high-risk, HER2-positive urogenitalcancer (adjuvant therapy)
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
thyroid cancer(see also brain, skin)--------------------------------------------------endometrial cancer
-------------------------------------------
(irofulven)EisaiWoodcliff Lake, NJ
thyroid cancer(see also ovarian, prostate)
efatutazone Daiichi SankyoParsippany, NJ
thyroid cancer(see also colorectal, lung)
Medicines in Development for Cancer
Medicines in Development Cancer 2012118
OTHER CANCERS
Product Name Sponsor Indication Development Status
EGEN-001 EGENHuntsville, AL
fallopian tube cancer, peritoneal cancer(see also colorectal, ovarian)
elagolix Abbott LaboratoriesAbbott Park, IL
Neurocrine BiosciencesSan Diego, CA
uterine leiomyoma
ENMD-2076 EntreMedRockville, MD
late-stage cancer(see also multiple myeloma, ovarian)
Femara®
letrozoleNovartis PharmaceuticalsEast Hanover, NJ
recurrent, metastatic endometrial cancer (combination therapy) (888) 669-6682
folate binding protein (E39) vaccine
Galena BiopharmaLake Oswego, OR
endometrial cancer(see also breast, ovarian)
fostamatinib(SYK inhibitor)
AstraZenecaWilmington, DE
Rigel PharmaceuticalsSouth San Francisco, CA
hematological malignancies(800) 236-9933
Gleevec®
imatinibNovartis PharmaceuticalsEast Hanover, NJ (see also lung, prostate, skin) (888) 669-6682
Inlyta®
axitinib New York, NY
thyroid cancer(see also kidney, liver)
Cambridge, MA
hematological malignancies
Istodax®
romidepsinCelgeneSummit, NJ
hematological malignancies(see also kidney, pancreatic, prostate)
(908) 673-9000
IXEMPRA® ixabepilone
Bristol-Myers SquibbPrinceton, NJ
endometrial cancer in clinical trials
™ruxolitinib Wilmington, DE
hematological malignancies(see also pancreatic)
KaloBios PharmaceuticalsSouth San Francisco, CA
hematological malignancies
Marqibo®
vincristine liposomalTalon TherapeuticsSan Mateo, CA
pediatric cancers(see also leukemia, lymphoma, skin)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 119
OTHER CANCERS
Product Name Sponsor Indication Development Status
(anti-CD19 mAb)AstraZenecaWilmington, DE
Gaithersburg, MD
hematological malignancies(800) 236-9933(301) 398-0000
MER-101 (zoledronic acid oral)
Merrion PharmaceuticalsWilmington, NC
bone metastaseswww/merrionpharma.com
Mirena®
levonorgestrel-releasingintrauterine system
Bayer HealthCare PharmaceuticalsWayne, PA
endometrial cancer, endometrial hyperplasia
(notch signaling pathwayinhibitor)
MerckWhitehouse Station, NJ
central nervous system (CNS) cancer in patients ages 3-21(see also breast)
(800) 672-6372
MK-2206(c-akt inhibitor)
Merck Whitehouse Station, NJ
inoperable/unresectable neuroendocrine tumors(see also breast)
(800) 672-6372
MLN0128 Millennium PharmaceuticalsCambridge, MA
hematological malignancies(see also solid tumors)
(NEDD8 inhibitor)Millennium PharmaceuticalsCambridge, MA
hematological malignancies(see aslo solid tumors)
motesanib Amgen thyroid cancer(see also breast, colorectal, lung)
moxetumomab pasudotox AstraZenecaWilmington, DE
Gaithersburg, MD
hematological malignancies(800) 236-9933(301) 398-0000
MSC1936369B EMD SeronoRockland, MA
hematological malignancies(800) 283-8088
Nexavar®
sorafenibBayer HealthCare PharmaceuticalsWayne, NJ
thyroid cancer(see also breast, colorectal, head/neck, kidney, leukemia, liver, lung, multiple myeloma, ovarian)--------------------------------------------------neuroendocrine tumors
-------------------------------------------
NiCord®
umbilical cord blood stem cell therapy
Gamida CellJerusalem, Israel
hematological malignancieswww.gamida-cell.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012120
OTHER CANCERS
Product Name Sponsor Indication Development Status
NTX-010 NeotropixMalvern, PA
neuroendocrine tumors(see also lung) www.neotropix.com
Opaxio™paclitaxel poliglumex
Cell TherapeuticsSeattle, WA
fallopian tube cancer, peritoneal cancer(see also brain, lung, ovarian, stomach)
OPR-003 EUSA PharmaLanghorne, PA
VaccinexRochester, NY
hematological malignancies
inhibitor)Farmingdale, NY
adrenocortical carcinoma(see also lung, ovarian) (631) 962-0600
PEG arginine deiminase Polaris PharmaceuticalsSan Diego, CA
pediatric cancer(see also liver, prostate, skin)
New York, NY
endometrial cancer(see also solid tumors)
New York, NY
endometrial cancer(see also solid tumors)
Nerviano Medical ServicesNerviano, Italy
thymoma www.nervianoms.com
phenoxodiol Marshall EdwardsSan Diego, CA
fallopian tube cancer (combination therapy)(see also ovarian, prostate)
PharmaMarMadrid, Spain
endometrial cancer(see also cervical, sarcoma) www.pharmamar.com
PTC299 PTC Therapeutics central nervous system (CNS) cancer in children(see also breast, solid tumors)
(908) 222-7000
RG7112(MDM2 antagonist)
RocheNutley, NJ
hematological malignancies(see also solid tumors)
RG7388(MDM2 inhibitor)
RocheNutley, NJ
hematological malignancies(see also solid tumors)
(mAb)RocheNutley, NJ
hematological malignancies
Medicines in Development for Cancer
Medicines in Development Cancer 2012 121
OTHER CANCERS
Product Name Sponsor Indication Development Status
(antibody drug conjugate)GenentechSouth San Francisco, CA
hematological malignancies
ridaforolimusCambridge, MA
MerckWhitehouse Station, NJ
endometrial cancer(see also breast, kidney, lung, prostate, sarcoma)
(800) 672-6372
rintatolimod Hemispherx BiopharmaPhiladelphia, PA
cancer vaccine adjuvant
injectionEUSA PharmaLanghorne, PA
bone metastases(see also breast, multiple myeloma, prostate, sarcoma)
(maytansin-loaded anti-CD19 mAb)
Bridgewater, NJ
Needham, MA
B-cell malignancies
Bridgewater, NJ
Exelixis South San Francisco, CA
endometrial cancer(see also breast)
(anti-CD38 naked mAb) Bridgewater, NJ
hematological malignancies
SB989 (pracinostat) Oakland, CA
hematological malignancies(see also leukemia, solid tumors)
siltuximab Janssen BiotechHorsham, PA
giant lymph node hyperplasia(see also multiple myeloma, prostate)
SOM230 (pasireotide)
Novartis PharmaceuticalsEast Hanover, NJ
carcinoid tumors
--------------------------------------------------meningioma, neuroendocrine tumors
(888) 669-6682-------------------------------------------
(888) 669-6682
sotatercept (ACE-011)
CelgeneSummit, NJ
cancer metastases(see also cancer-related) (908) 673-9000
SPRYCEL®
dasatinibBristol-Myers SquibbPrinceton, NJ
pediatric cancer(see also brain, breast, pancreatic, prostate)
in clinical trials
Medicines in Development for Cancer
Medicines in Development Cancer 2012122
OTHER CANCERS
Product Name Sponsor Indication Development Status
StemEx®
carlecortemcel-L(Orphan Drug)
Gamida CellJerusalem, Israel
Teva North AmericaNorth Wales, PA
hematological malignancies(Fast Track) (888) 838-2872
TAK-901(aurora kinase B inhibitor)
Millennium PharmaceuticalsCambridge, MA
hematological malignancies
Tarceva®
erlotinibGenentechSouth San Francisco, CA
Farmingdale, NY
gynecological cancer (see also brain, breast, head/neck, leukemia, liver, lung) (631) 962-0600
telapristone Repros Therapeutics uterine leiomyoma
terameprocol Erimos Pharmaceuticals hematological malignancies (intravenous)(see also brain, cervical, head/neck, solid tumors)
TG02Oakland, CA
Tragara PharmaceuticalsSan Diego, CA
hematological malignancies
tivantinib (ARQ 197)
ArQuleWoburn, MA
Daiichi SankyoParsippany, NJ
germ cell and embryonal neoplasms(see also colorectal, kidney, liver, lung, pancreatic, sarcoma)
(dovitinib)Novartis PharmaceuticalsEast Hanover, NJ
second-line endometrial cancer, urothelial carcinoma(see also breast, kidney, multiple myeloma, prostate, skin)
(888) 669-6682
(ENG protein inhibitor)TRACON PharmaceuticalsSan Diego, CA
fallopian tube cancer, peritoneal cancer(see also breast, ovarian, prostate)
trebananib (AMG386) Amgen fallopian tube cancer, peritoneal cancer(see also breast, colorectal, kidney, liver, stomach)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 123
OTHER CANCERS
Product Name Sponsor Indication Development Status
ulipristalParsippany, NJ
uterine leiomyoma
VB-111 VBL TherapeuticsOr Yehuda, Israel
thyroid cancer(see also brain) www.vblrx.com
Velcade®
bortezomibMillennium PharmaceuticalsCambridge, MA
adenocarcinoma (combination therapy)(see also leukemia, lymphoma, cancer-related)
volasertibPharmaceuticals
urogenital cancer
Votrient™pazopanib
GlaxoSmithKline fallopian tube cancer, peritoneal cancer(see also kidney, ovarian)
Xgeva™denosumab
Amgen prevention of bone metastases in men with castrate-resistant prostate cancer(see also cancer-related, multiple myeloma)--------------------------------------------------prevention of bone metastases in women with early-stage breast cancer--------------------------------------------------giant cell tumor of bone
application submitted
-------------------------------------------
-------------------------------------------
Zelboraf®
vemurafenibGenentechSouth San Francisco, CA
PlexxikonBerkeley, CA
inoperable/unresectable thyroid cancer(see also brain, colorectal)
Zolinza®
vorinostatMerckWhitehouse Station, NJ
gynecological cancer, peritoneal cancer(see also breast, leukemia, lung, lymphoma, multiple myeloma)
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012124
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
Apogee BiotechnologyHummelstown, PA
late-stage disease
(nab®
CelgeneSummit, NJ (908) 673-9000
AFX-9901 Afecta PharmaceuticalsIrvine, CA
in clinical trials
AGS-6MF AgensysSanta Monica, CA
Astellas Pharma US
AGS-16M8F AgensysSanta Monica, CA
Astellas Pharma US
ALT-836 Altor BioScienceMiramar, FL
Bristol-Myers SquibbPrinceton, NJ
anti-LAG3(BMS-986016)
Bristol-Myers SquibbPrinceton, NJ
(docetaxel for injectable emulsion)
ADVENTRX PharmaceuticalsSan Diego, CA
ARRY-300(MEK inhibitor)
Array BioPharmaBoulder, CO
Novartis PharmaceuticalsEast Hanover, NJ
(888) 669-6682
ARRY-382(c-fms antagonist)
Array BioPharmaBoulder, CO
CelgeneSummit, NJ
metastatic cancer
(908) 673-9000
AVL-292(Btk inhibitor)
CelgeneSummit, NJ
(see also leukemia, lymphoma)(908) 673-9000
B7-2/GM-CSFcancer gene therapy vaccine
NuVax Therapeutics
(PET imaging)Bayer HealthCare PharmaceuticalsWayne, NJ
cancer (diagnosis)
Medicines in Development for Cancer
Medicines in Development Cancer 2012 125
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
cancer vaccineVancouver, Canada www.immunitor.com
cancer vaccine Cytokine PharmaSciencesKing of Prussia, PA (610) 687-1776
carboxyamidotriazole orotate(CTO)
Tactical TherapeuticsNew York, NY
Cleveland BioLabsBuffalo, NY
Eli LillyIndianapolis, IN
CDX-301(Fms-like tyrosine kinase 3 ligand)
Celldex TherapeuticsNeedham, MA
cell therapy Cell MedicaLondon, United Kingdom
Center for Cell and Gene Therapywww.cellmedica.co.uk
CEN-109 Centella TherapeuticsPalo Alto, CA
cancer (diagnosis)www.centellatx.com
Chk1 inhibitor Eli LillyIndianapolis, IN
c-Met inhibitor Eli LillyIndianapolis, IN
c-Met mAb Eli LillyIndianapolis, IN
CSF-1R mAb Eli LillyIndianapolis, IN
Bridgewater, NJ
curmucin Signpath PharmaQuakertown, PA (267) 772-0107
Eli LillyIndianapolis, IN
Medicines in Development for Cancer
Medicines in Development Cancer 2012126
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
cytotropic heterogeneous molecular lipids(CHML)
Glory PharmaceuticalsVienna, VA
DM-CHOC-PEN Dekk-TecNew Orleans, LA
EndocyteWest Lafayette, IN www.endocyte.com
Bristol-Myers SquibbPrinceton, NJ
Eli LillyIndianapolis, IN
fenretinide intravenous CerRxwww.cerrx.com
FGF receptor inhibitor Eli LillyIndianapolis, IN
ACEA BiosciencesSan Diego, CA (866) 308-2232
gemcitabine prodrug Eli LillyIndianapolis, IN
(cancer vaccine) Louisville, CO
GSK3 inhibitor Eli LillyIndianapolis, IN
San Diego, CA
Quintileswww.huyabio.com
hedgehog antagonist Eli LillyIndianapolis, IN
hTERT plasmid DNA cancer vaccine
MerckWhitehouse Station, NJ
VicalSan Diego, CA
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 127
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
Bristol-Myers SquibbPrinceton, NJ
imaging agentMayo ClinicRochester, MN
NaviscanSan Diego, CA
cancer (diagnosis)www.mayoclinic.org
RxCarlsbad, CA
JAK2 inhibitor Eli LillyIndianapolis, IN
masoprocol TriAct TherapeuticsSan Francisco, CA
MK-8033(c-Met/RON protein inhibitor)
MerckWhitehouse Station, NJ (800) 672-6372
new molecular entity Eli LillyIndianapolis, IN
notch inhibitor Eli LillyIndianapolis, IN
notch inhibitor Bristol-Myers SquibbPrinceton, NJ
OPB-31121 Otsuka America PharmaceuticalRockville, MD
p38 MAP inhibitor (1) Eli LillyIndianapolis, IN
p38 MAP inhibitor (2) Eli LillyIndianapolis, IN
p70/AKT inhibitor Eli LillyIndianapolis, IN
Puma BiotechnologyLos Angeles, CA
Medicines in Development for Cancer
Medicines in Development Cancer 2012128
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
Phoenix Biotechnology
New York, NY
PD-0332991New York, NY
(gamma-secretase inhibitor) New York, NY
(sonic hedgehog pathway inhibitor)
New York, NY
(CD137 antigen agonist mAb) New York, NY
Proleukin®
aldesleukin(subcutaneous)
Prometheus LaboratoriesSan Diego, CA
(888) 892-8391
PRT6207Cambridge, MA
Portola PharmaceuticalsSouth San Francisco, CA
RON mAb Eli LillyIndianapolis, IN
Bridgewater, NJ
(JAK2 inhibitor) Oakland, CA
SCH-900776 MerckWhitehouse Station, NJ (800) 672-6372
SMO antagonist (BMS-833923)
Bristol-Myers SquibbPrinceton, NJ
SR13668Menlo Park, CA
cancer (prevention) Phase 0
V930/V932(plasmid DNA vaccine)
MerckWhitehouse Station, NJ
VicalSan Diego, CA
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012 129
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
VEGFR3 mAb Eli LillyIndianapolis, IN
Bridgewater, NJ
XmAb® anti-cancer mAb Pharmaceuticals
XencorMonrovia, CA
Medicines in Development for Cancer
Report
current as of May 16, 2012. -
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info
Copyright © 2012 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.
Medicines in Development Cancer 2012130
Glossary
actinic keratoses—Roughness and thicken-ing of the skin caused by overexposure to the
skin cancer called squamous cell carcinoma.
adenocarcinoma—Malignant tumor derived from a gland or glandular tissue.
adjunctive treatment—An auxiliary treatment that is secondary to the main treatment.
adjuvant—A substance or drug that aids another substance in its action.
allogeneic—Refers to having cell types that are distinct and cause reactions in the immune system.
application submitted—An application for marketing has been submitted by the company to the Food and Drug Administration (FDA).
ascites
the tissues lining the abdomen and abdominal organs (the peritoneal cavity).
basal cell cancer—Cancer of the lower layers of the skin.
B-cell—A class of white blood cells important to the body’s immune system.
biliary—Relating to bile.
carcinoma—A malignant tumor that arises from epithelial tissues, such as skin.
cervical—Relating to the neck of the uterus.
chemoprotection—A therapeutic technique in which bone marrow cells are removed from an individual with cancer and are genetically modi-
before being returned to the donor.
cholangiocarcinoma—A malignancy of the biliary duct system that may originate in the liver and extrahepatic bile ducts. More than 90 percent are adenocarcinomas, and the remain-der are squamous cell tumors. Cholangiocarci-
walls of the ducts. Each year, approximately
is 1 case per 100,000 people per year.
cutaneous—Pertaining to the skin.
dysplasia—Abnormal tissue development.
gastric—Of or relating to the stomach.
GIST
Although these cancers can arise anywhere
stomach (60% to 70%) and less commonly in the small intestine (20% to 30%). The rest are found in the esophagus, large intestine, rectum, and anus. About 80% of people diag-
more common in men. Blacks are more likely
glioblastoma—A fast growing and highly malignant type of brain tumor arising from glial (supporting) cells within the brain. There are
-tion per year in the United States.
glioma—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors and are frequently malignant.
graft-versus-host disease (GVHD)—A complication in bone marrow transplants where immune system cells attack the transplant recipient’s tissues.
head and neck cancer—The term given to a variety of malignant tumors that develop in the mouth, throat, paranasal sinuses, nasal cavity, larynx, and salivary glands. Many authorities also include skin tumors of the face and neck and tumors of the cervical lymph nodes. There are more than half a million survivors of oral, head, and neck cancer living in the United States today.
hematological malignancies—Cancers of the blood or blood-forming tissues, such as leuke-
mia, Hodgkin’s and non-Hodgkin’s lympho-
mas multiple
myeloma, myelodysplasia and myeloprolifera-tive disorders.
hepatocellular cancer/carcinoma—A cancer that begins in the liver cells.
hyperuricemia—An abnormally high uric acid level in the blood.
imaging agent—A substance used to enhance x-ray images of organs and spaces in the body.
intraepithelial neoplasia, anal (AIN) & cervi-
cal (CIN)
human papillomavirus infection in the anal canal and appears to be driven by high viral
of its natural history resembles that of cervical intraepithelial neoplasia. Dysplasia and cervi-
terms or names for the same condition—it is a precursor to cervical cancer
mild, moderate or severe.
Kaposi’s sarcoma—A rare, malignant skin
can be accompanied by fever, enlarged lymph nodes and gastrointestinal problems.
Leiomyoma—A benign neoplasm derived from smooth muscle.
leukemia—A form of cancer in which abnor-mally growing white blood cells are scattered throughout the body and bone marrow. They can take over the marrow and prevent it from making enough normal blood cells (white, red and platelets), leaving the patient highly susceptible to serious infections, anemia and bleeding episodes. The cells can also spill into
function of other organs. The four main types acute lympho blastic leuke-
mia (ALL), acute myeloid leukemia (AML),
chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The acute types have a rapid onset, and overwhelming infection or blood loss can cause death. The chronic forms progress much more slowly.
lung cancer—The leading cause of cancer deaths in both men and women. There are several types of lung cancer, the most common being squamous cell carcinoma, small (oat) cell carcinoma, adenocarcinoma and large cell
Medicines in Development Cancer 2012 131
Glossary
carcinoma. Each has a different growth pattern and response to treatment. The squamous cell, small cell and large cell types are all strongly associated with tobacco abuse.
lymphoma—Cancers in which the cells of lym-phoid tissue, found mainly in the lymph nodes and spleen, multiply unchecked. Lymphomas
-acterized by a particular kind of abnormal cell, and non-Hodgkin lymphomas, which vary in their malignancy according to the nature and activity of the abnormal cells. Mantle cell lym-
phoma is a type of non-Hodgkin lymphoma.
macroglobulinemia—A disorder in which plasma cells produce an excessive quantity of macroglobulins (large antibodies) that ac-
of abnormal, cancerous lymphocytes and plasma cells. Men are affected more often than
mastocytosis—A condition characterized by
body. Mast cells are connective tissue cells which release chemicals including histamine that are very irritating and cause itching, swell-
medullary—Relating to the medulla (any soft marrow-like structure, especially the innermost part) or marrow.
melanoma—A cancer made up of pigmented (usually brown-colored) skin cells anywhere in the body.
mesothelioma—A tumor of the lining of the lung and chest cavity (the pleura).
metastases/metastatic—Areas of secondary cancer that have spread from the primary or original cancer site.
mucositis—The swelling, irritation, and ulcer-ation of the mucosal cells that line the digestive tract. Mucositis can occur anywhere along the
can be a very troublesome and painful side effect of chemotherapy.
multiple myeloma—A malignant condition of middle to old age, characterized by the uncon-trolled proliferation and disordered function of plasma cells in the bone marrow. The condi-tion, which makes the patient particularly prone to infection, is rare, with about three new cases annually per 100,000 population.
myeloablation—A severe form of myelosup-pression, a condition in which bone marrow activity is decreased, resulting in fewer red
a side effect of some cancer treatments.
myelodysplastic syndromes (MDS)—Blood disorders that ultimately are fatal. Patients usually succumb to infections or bleeding. The term “preleukemia” has been used to describe these disorders.
neoadjuvant therapy—Chemotherapy, radia-tion therapy, or hormone therapy given before the primary or main treatment. Neo-adjuvant therapy, like chemotherapy and radiation therapy, is often given before surgery to reduce the size of a tumor or to make surgery less complicated.
neuroblastoma—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system responsible for certain automatic body functions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.
osteosarcoma—Cancer of the bone that oc-curs predominantly in adolescents and young
children.
peritoneal—Relating to the peritoneum, the membrane that lines the abdominal cavity and covers most of the abdominal organs.
Phase 0—First-in-human trials conducted in accordance with FDA’s 2006 guidance on
studies designed to speed up development of promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies.
Phase I—Safety testing and pharmacologi-
humans.
Phase II -tion of side effects of new drugs in humans.
Phase III—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.
prolactinoma—A noncancerous pituitary tumor that produces a hormone called prolac-tin, which results in too much prolactin in the blood.
refractory—Resistant to treatment or cure.
sarcoma—A malignant tumor that arises from deep body tissues, such as muscle, bone or
T-cell—One of two main classes of white blood cells called lymphocytes, which are important
thrombocytopenia—A reduction in the number of platelet cells in the blood, which causes a tendency to bleed, especially from the smaller blood vessels.
thymoma—Although rare, thymomas are the most common tumor of the thymus, a small organ located in the upper chest just below the neck that produces certain types of white blood cells (lymphocytes) before birth and during childhood. Thymomas arise from thymic epithelial cells, which make up the covering of
invasive. They affect men and women equally and are usually diagnosed between the ages
children.
unresectable—Unable to be removed (re-sected) by surgery.
Medicines in Development Cancer 2012132
Selected Facts about Cancer in the United States
-ity, and poor nutrition, and thus could be prevented.
Studies have shown that pain occurs in 30 percent of all cancer patients, regardless of the stage of the disease, and 90 percent of patients with advanced cancer experience severe pain. Half of patients may be undertreated for cancer pain.2
The most common cause of cancer-related pain is from metastases to the bone. Up to 80 percent of cancer patients with bone metastases
structures may cause the most severe pain. The third most common cause of pain associated with cancer result from chemotherapy, radiation, or surgery.2
Breakthrough pain—pain that occurs even when taking regular pain medication—is common in cancer patients. Breakthrough cancer pain
-
3
Overview1
Pain
Costs1
Medicines in Development Cancer 2012 133
New Cancer Cases/Deaths1
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
All Sites .................................................................................. 1,638,910 ..................................................................................... Male ............................................................................. ..................................................................................... 301,820 Female ......................................................................... .....................................................................................
Acute Lymphocytic Leukemia .......................................................... ......................................................................................... Male ................................................................................. ............................................................................................ 820 Female ............................................................................. 2,600 ............................................................................................ 620
Acute Myeloid Leukemia ............................................................... 13,780 ....................................................................................... 10,200 Male ................................................................................. ......................................................................................... Female ............................................................................. .........................................................................................
Bladder Cancer .............................................................................. ....................................................................................... Male ............................................................................... ....................................................................................... Female ........................................................................... 17,910 .........................................................................................
Bone Cancer (and joints) ................................................................. 2,890 ......................................................................................... Male ................................................................................. 1,600 ............................................................................................ 790 Female ............................................................................. 1,290 ............................................................................................ 620
Brain Cancer (and other nervous system) ..................................... 22,910 ....................................................................................... 13,700 Male ............................................................................... 12,630 ......................................................................................... 7,720 Female ........................................................................... 10,280 .........................................................................................
Breast Cancer .............................................................................. 229,060 ....................................................................................... 39,920 Male ................................................................................. 2,190 ............................................................................................ Female ......................................................................... 226,870 .......................................................................................
Cervical and Uterine Cancers ........................................................ ....................................................................................... 12,230 Male .......................................................................................— ...............................................................................................— Female ........................................................................... ....................................................................................... 12,230
Chronic Lymphocytic Leukemia ..................................................... 16,060 ......................................................................................... Male ................................................................................. ......................................................................................... 2,730 Female ............................................................................. .........................................................................................
Chronic Myeloid Leukemia .............................................................. ............................................................................................ 610 Male ................................................................................. 3,210 ............................................................................................ 370 Female ............................................................................. 2,220 ............................................................................................
Colorectal Cancer ........................................................................ ....................................................................................... Male ............................................................................... ....................................................................................... Female ........................................................................... .......................................................................................
Selected Facts about Cancer in the United States
Medicines in Development Cancer 2012134
Selected Facts about Cancer in the United States
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Esophageal Cancer ....................................................................... ....................................................................................... Male ............................................................................... ....................................................................................... Female ............................................................................. ......................................................................................... 3,030
Kidney Cancer (and renal pelvis) .................................................. ....................................................................................... Male ............................................................................... ......................................................................................... Female ........................................................................... .........................................................................................
Leukemia (all types) ...................................................................... ....................................................................................... Male ............................................................................... 26,830 ....................................................................................... Female ........................................................................... 20,320 .......................................................................................
Liver Cancer .................................................................................. 28,720 ....................................................................................... Male ............................................................................... 21,370 ....................................................................................... 13,980 Female ............................................................................. .........................................................................................
Lung Cancer (and bronchus) ....................................................... 226,160 ..................................................................................... Male .............................................................................. ....................................................................................... Female ......................................................................... 109,690 .......................................................................................
Lymphoma (all types) .................................................................... 79,190 ....................................................................................... 20,130 Male ............................................................................... ....................................................................................... 10,990 Female ........................................................................... 36,070 .........................................................................................
Lymphoma (non-Hodgkin’s) ........................................................... 70,130 ....................................................................................... Male ............................................................................... 38,160 ....................................................................................... 10,320 Female ........................................................................... 31,970 ......................................................................................... 8,620
Melanoma-Skin Cancer ................................................................. ......................................................................................... 9,180 Male ............................................................................... ......................................................................................... 6,060 Female ........................................................................... 32,000 ......................................................................................... 3,120
Multiple Myeloma ........................................................................... 21,700 ....................................................................................... 10,710 Male ............................................................................... 12,190 ......................................................................................... 6,020 Female ............................................................................. .........................................................................................
Ovarian Cancer ............................................................................. 22,280 ....................................................................................... Male .......................................................................................— ...............................................................................................— Female ........................................................................... 22,280 .......................................................................................
Pancreatic Cancer ......................................................................... ....................................................................................... 37,390 Male ............................................................................... 22,090 ....................................................................................... Female ........................................................................... 21,830 .......................................................................................
New Cancer Cases/Deaths1 continued
Medicines in Development Cancer 2012 135
Selected Facts about Cancer in the United States
New Cancer Cases/Deaths1 continued
Sources:
1. American Cancer Society (www.cancer.org)
2. Remedy Health Media, LLC (www.healthcommunities.com)
3. American Pain Foundation (www.painfoundation.org)
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Prostate Cancer ........................................................................... ....................................................................................... 28,170 Male ............................................................................. ....................................................................................... 28,170 Female ...................................................................................— ...............................................................................................—
Stomach Cancer ............................................................................ 21,320 ....................................................................................... Male ............................................................................... 13,020 ......................................................................................... 6,190 Female ............................................................................. 8,300 .........................................................................................
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the
compounds that enter preclinical testing make
is approved for sale.
including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.
the laboratory, medicines are usually devel-
Preclinical Testing. A pharmaceutical com-pany conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the com-pound is evaluated for safety.
Investigational New Drug Application (IND). After completing preclinical testing, a company
Administration (FDA) to begin to test the drug
is manufactured. All clinical trials must be
conducted. Progress reports on clinical trials must be submitted at least annually to FDA and
Clinical Trials, Phase I. These tests usually involve about 20 to 100 healthy volunteers. The
safe dosage range. The studies also determine how a drug is absorbed, distributed, metabo-lized, and excreted as well as the duration of its action.
Clinical Trials, Phase II.
volunteer patients (people with the disease) assess a drug’s effectiveness and determine
Clinical Trials, Phase III. This phase usually
hospitals. Physicians monitor patients closely to
New Drug Application (NDA)/Biologic
License Application (BLA). Following the completion of all three phases of clinical trials,
NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness.
information that the company has gathered. Applications typically run 100,000 pages or more.
Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials
Discovering and developing safe and effective
process. PhRMA member companies invested
development in 2011.
The Drug Discovery, Development and Approval Process
Developing a new medicine takes an average of 10-15 years;
For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process